Published in final edited form as:

Cell Mol Life Sci. 2008 November ; 65(22): 3564–3591. doi:10.1007/s00018-008-8222-z.

Cell penetrating peptide inhibitors of Nuclear Factor-kappa B

J. S. Orange^a and M. J. May^{b,*}

^aDepartment of Pediatrics, University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia 3615 Civic Center Blvd., ARC 1016H, Philadelphia, PA 19104 (USA)

^bDepartment of Animal Biology and The Mari Lowe Center for Comparative Oncology, University of Pennsylvania School of Veterinary Medicine, 3800 Spruce Street (OVH 200E), Philadelphia, PA 19104 (USA)

Abstract

The nuclear factor kappa B (NF-κB) transcription factors are activated by a range of stimuli including pro-inflammatory cytokines. Active NF-κB regulates the expression of genes involved in inflammation and cell survival and aberrant NF-κB activity plays pathological roles in certain types of cancer and diseases characterized by chronic inflammation. NF-κB signaling is an attractive target for the development of novel anti-inflammatory or anti-cancer drugs and we discuss here how the method of peptide transduction has been used to specifically target NF-κB. Peptide transduction relies on the ability of certain small cell-penetrating peptides (CPPs) to enter cells, and a panel of CPP-linked inhibitors (CPP-Is) has been developed to directly inhibit NF-κB signaling. Remarkably, several of these NF-κB-targeting CPP-Is are effective *in vivo* and therefore offer exciting potential in the clinical setting.

Keywords

Nuclear Factor kappa B; I kappa B Kinase; cell penetrating peptide; peptide transduction; signal transduction

Introduction

Diverse stimuli activate the nuclear factor kappa B (NF-κB) transcription factors. These include pro-inflammatory cytokines, signals that activate innate and adaptive immune receptors, and various cellular stresses [1,2]. In turn, NF-κB regulates the expression of many genes involved in responses ranging from inflammation and innate and adaptive immunity, to cell growth, survival, and proliferation [1–3]. Under normal circumstances, NF-κB activation occurs rapidly and transiently; dysregulated or constitutive NF-κB activity, however, has been functionally linked to the development of diseases, including those characterized by chronic inflammation, as well as auto-immunity and certain cancers [2–5]. In light of this important detrimental role of aberrant NF-κB signaling, a major goal of many pharmaceutical enterprises is the development of therapeutically effective, highly specific inhibitors of NF-κB. Over seven hundred natural and synthetic compounds that block NF-κB activity have been identified and a number of drugs targeting this pathway have been described [5,6]. Because most of these compounds either lack specificity or disrupt the normal physiological functions of NF-κB, they are less than ideal candidates for clinical use.

As our understanding of the complexity of NF- κ B signaling expands, promising novel molecular targets for the development of specific inhibition strategies continue to emerge. For example, the demonstration that NF- κ B activation occurs through two major transduction mechanisms, named the classical and non-canonical pathways, that utilize distinct upstream signaling components has revealed novel targets that could be exploited to develop pathway-specific drugs [2,3,7–9]. In addition to the obvious therapeutic value of such selective reagents, the ability to directly inhibit specific signaling components in the many pathways leading to NF- κ B activation will greatly assist basic researchers trying to dissect these mechanisms *in vitro* and *in vivo* in models of disease.

A method for introducing exogenous bioactive macromolecules into cells has been used effectively to specifically inhibit NF- κ B signaling. Named peptide transduction, this methodology not only provides researchers with a convenient means to manipulate NF- κ B signaling in cells and *in vivo*, but also may aid in identifying and validating novel selective targets for the development of a new generation of highly specific drugs targeting NF- κ B. Peptide transduction hinges on the ability of an expanding group of small peptides to cross the plasma membrane and enter cells [10–14]. These are named cell-penetrating peptides (CPPs) and include both naturally occurring and synthetic sequences. The utility of this approach for the detailed study of signal transduction pathways rests in the fact that CPPs can be conjugated to a wide range of bioactive cargos, allowing large exogenous macromolecules that would otherwise be excluded from cells to rapidly enter through a process called membrane transduction. These cargos are then able to immediately exert their biological effects directly on their molecular targets within the cell. This “Trojan Horse” approach has been used extensively to manipulate signal transduction mechanisms *in vitro* and *in vivo* and a number of CPP-linked inhibitors (herein referred to as CPP-Is) that directly target NF- κ B signaling have been developed.

In the following section we will briefly introduce the basic principals of peptide transduction, focusing our discussion on the CPPs that have been used to study NF- κ B signaling. We will then discuss NF- κ B signaling and describe in depth the CPP-Is that have been developed to target NF- κ B.

Peptide transduction

The ability to manipulate proteins in living cells is a crucial method for studying protein function and for validating potential drug targets. Some approaches require the introduction of bioactive material into cells. This material may include DNA constructs encoding mutated versions of effector proteins or reagents, such as antisense or short-interfering RNA (siRNA), to knock down gene expression. Various techniques overcome the natural resistance of the plasma membrane to exogenous material and the most widely used of these are lipid-based transfection, viral vectors, electroporation, and microinjection. Despite the almost universal application of these techniques, they have limitations. For example they can be (i) inefficient and result in low levels of transfection; (ii) cytotoxic or harsh and cause excessive cell loss; (iii) complex in that they might require specialized equipment or reagents and involve extensive optimization of conditions; (iv) are often not effective for primary or non-dividing cells; (v) capable of drastically altering cell activation state in their own right; and (vi) unreliable or not applicable due to organismal toxicity for *in vivo* studies of protein function or target validation.

Peptide transduction offers an attractive alternative approach for the introduction of bioactive reagents directly into living cells where they can immediately exert their effects. Biophysical, biochemical, and *in vitro* and *in vivo* studies demonstrate that peptide transduction largely overcomes the problems associated with the more traditional transfection methods. Thus, CPP-mediated transduction is generally non-toxic within the effective concentration ranges, it can rapidly deliver a diverse assortment of molecular cargos into all cell types tested (including

primary and nondividing cells), and, most importantly, it is highly effective *in vivo* where it can direct bioactive cargo into all tissues including the brain [10–15].

Cell-penetrating peptides (CPPs)

Naturally occurring and synthetic CPPs, fall into three classes based upon their biophysical properties: cationic (so named for the presence of arginine or lysine residues), hydrophobic, and amphipathic peptides (Table 1). The distinct characteristics of these CPPs facilitate their uptake across the plasma membrane and the best studied in this regard are the cationic peptides that contain a number of positively charged arginine or lysine residues. Even synthetic CPPs of seven to 11 residues composed solely of arginine (Poly-Arg) or lysine (Poly-Lys) enter cells, underscoring the importance of cationic residues for uptake [10,16,17]. Of the three classes of CPPs, members of both the cationic and hydrophobic groups have been extensively used to manipulate NF- κ B signaling. To date, however, none of the amphipathic CPPs has been used to deliver cargo targeting NF- κ B signaling and these will not be further discussed here [see [11–15,18] for reviews].

Five CPPs and their derivatives have been used in studies of NF- κ B signaling (Table 1). These include the first membrane-permeable peptide identified, which was the sequence located between residues 47 and 57 of the human immunodeficiency virus (HIV)-1 TAT protein that was necessary and sufficient for cell permeation of the entire TAT protein [19,20] and was the minimal domain required for traversing cell membranes [21]. This TAT fragment is now widely utilized as a CPP, including for the transduction of distinct peptide or protein cargos that block components of the NF- κ B pathway (Table 2). A second, widely used cationic CPP utilized to study NF- κ B signaling is derived from the third α -helix of the *Drosophila* homeodomain transcription factor Antennapedia. The segment between residues 43 and 58 of Antennapedia is sufficient for membrane transduction of the entire protein [22,23] and is commonly named AntP (or penetratin). A third cationic CPP is the synthetic peptide transduction domain (PTD)-5 [16], which enters some cell types more efficiently than TAT or AntP. The transducing ability of PTD-5 requires the positively charged RRQRR motif, which is derived from the parent TAT fragment (underlined in Table 1). The last of the cationic CPPs used to deliver cargo targeting NF- κ B signaling are synthetic poly-arginine or poly-lysine homopolymers that have been reported to be more efficient than either TAT or AntP for *in vivo* delivery [16,24,25].

The only hydrophobic CPP used to deliver cargo to target the NF- κ B pathway is derived from the hydrophobic region (h-region) of the signal sequence of Kaposi fibroblast growth factor (kFGF, also known as FGF-4) and is named the membrane translocating sequence (MTS) [26]. Although MTS is considered less effective than the cationic peptides [14], it remains a frequently used CPP for signal transduction research.

The mechanisms of transduction are distinct for each class of CPP. Initially, uptake of cationic CPPs was thought to be energy-, receptor-, and endocytosis-independent [10,19,20,22,23,27,28], however it is now clear that endocytosis or macropinocytosis is involved [29–33]. The initial association of TAT, AntP, poly-R, or poly-K with the plasma membrane occurs through an ionic interaction between the positively charged residues in the peptides and negatively charged membrane phospholipids and proteoglycans, including heparan sulfate [16,30,34,35]. In contrast, the hydrophobic CPP MTS does not rely on endocytosis for in membrane transduction [26,32]. Studies of MTS and other related hydrophobic signal sequence CPPs have suggested that the secondary conformation is important for transduction and a current model is that MTS forms an α helical hairpin that interacts with membrane lipids, then unloops to a transmembrane conformation, penetrates the phospholipid bilayer, and carries the cargo into the cell [36].

CPPs transduce most types of cells in the absence of cytotoxicity, although high concentrations (>100 μ M) of TAT and AntP have been shown to be toxic to some cell types [37,38]. When conjugated with bioactive cargo, cytotoxicity that is dependent upon either the CPP used, the length and nature of the cargo molecule, or the method used to couple the cargo to the CPP (see below) has been reported for high concentrations of each of the separate classes of CPPs [37–39]. Furthermore, certain CPP-cargo combinations may be cytotoxic for some cell types but well tolerated by others [37–39]. In this regard, we have consistently observed that treatment of the Jurkat T cell line with AntP leads to cargo-independent cell death even at low concentrations of the peptide; we have not, however, observed similar toxicity in any other cell line or primary cell type that we have tested (unpublished observations). Although the toxic effects on immune cells in culture may only occur in certain cell lines, caution must clearly be taken in distinguishing effects of CPP-Is that are target-specific and effects that may be due to nonspecific toxicity. Consequently, any strategy involving the use of CPPs to deliver bioactive cargo should first test for toxicity using a range of CPPs, distinct coupling methods and a full range of concentrations of the peptides before conclusions regarding target-specific effects can be drawn.

The range of bioactive cargo delivered by CPPs

CPPs can deliver a range of diverse cargos and influence many intracellular processes [12, 13,18,40]. The CPPs in Table 1 have been successfully used to deliver cargos ranging in size from small therapeutic molecules, such as doxorubicin, to liposomes over 200 nm in diameter [13]. Other cargos that have been delivered by CPPs include antisense oligo-nucleotides, siRNAs, plasmids, viral particles and 40nm metallic beads [12,13,18,40]. Three methods are commonly used to conjugate a bioactive cargo with a CPP (Fig. 1): (i) chemical synthesis of chimeric fusions of cargo peptides with the CPPs, (ii) covalent attachment of the CPP and cargo by a chemical linker and (iii) cloning and bacterial expression of recombinant proteins using plasmids harboring the CPP as a “tag” [40]. Due to the relative ease of synthesis and the nature of the separate targets, most NF- κ B studies have utilized the first of these approaches to generate tandem fusions of the CPP with the appropriate peptide cargo. However, covalent linkage using a thiazolidine ring as the bridging moiety has also been used for delivering peptides targeting the NF- κ B pathway [41]. The third method of generating CPP-tagged recombinant proteins through bacterial expression and protein purification is most commonly used to generate CPPs conjugated to whole proteins. CPPs have been used extensively to deliver small peptides and whole proteins targeting diverse signal transduction pathways and it is this peptide- and protein-transducing capability of CPPs that has been exploited to target the NF- κ B pathway.

CPPs function *in vivo*

A remarkable feature of peptide transduction technology is the ability of CPPs to effectively deliver bioactive cargo *in vivo*. Work from several laboratories demonstrated that TAT-mediated delivery of β -galactosidase (β -gal) *in vivo* was effective with β -gal activity detected in all tissues including the brain after intravenous (i. v.) [42], intraperitoneal (i. p) [43], or oral administration [44] in mice. Furthermore, comparison of TAT- and viral-mediated transduction of β -gal to the rat salivary gland revealed that 100% of cells were transduced by TAT, whereas only 30 to 50% expressed β -gal following viral delivery [45–47]. TAT has also been used to deliver physiologically relevant cargos targeting signaling mechanisms *in vivo*, thereby laying the groundwork for clinical investigation of CPP-Is in animal models of disease [48–50]. Although the majority of published *in vivo* studies have used TAT as the CPP, other CPPs are also effective. Cre recombinase has been delivered *in vivo* by fusion to MTS and this resulted in excision in transgenic mice of loxP-flanked gene segments in all tissues examined [51]. Furthermore, AntP has been utilized *in vivo* to transduce peptide cargos that functioned to ameliorate symptoms in several disease models in mice [52]. Taken together, these reports

establish CPP-mediated protein and peptide transduction as a powerful approach to block signaling pathways in animal models of disease.

CPP inhibitors of NF- κ B signaling

NF- κ B signaling—NF- κ B proteins are a family of five structurally related transcription factors named p65 (RelA), RelB, c-Rel, p50 (NF- κ B1) and p52 (NF- κ B2) [1–3]. These proteins homo- or heterodimerize to generate either transcriptionally active (for example, p50:p65, p52:RelB) or repressive (for example, p50:p50) versions of NF- κ B. Each of the NF- κ B subunits contains a highly conserved Rel homology domain (RHD) that facilitates DNA binding, dimerization, and interaction with the inhibitory I κ B proteins. RelB, p65, and c-Rel are each translated in their mature forms; whereas p50 and p52 are the processed NH₂-termini of the longer precursor proteins p105 and p100, respectively. Constitutive processing of p105 maintains a constant cellular pool of p50; whereas p100 processing to p52 occurs only in response to a specific subset of signals.

In resting cells, NF- κ B proteins are maintained inactive in the cytosol through interaction with the I κ B proteins that mask a nuclear localization sequence (NLS) in the NF- κ B subunits. I κ Bs themselves belong to a family of proteins hallmarked by multiple ankyrin repeat domains that facilitate their binding to the RHDs of the NF- κ B proteins. The prototypic I κ B protein is I κ B α and the family also contains I κ B β , I κ B ϵ , and the COOH-termini of p100 and p105 that function as I κ Bs in certain NF- κ B complexes [2,3]. NF- κ B activation is initiated by phosphorylation of the I κ Bs leading to their ubiquitination and then degradation by the proteasome. For p100 and p105, only their I κ B-like COOH-termini are degraded, leaving the NH₂-termini (p52 and p50 respectively) intact. Once freed from I κ , NF- κ B translocates to the nucleus where it binds to target gene promoters and regulates gene expression. The kinases that phosphorylate I κ B proteins are components of the I κ B-kinase (IKK) complex that consists of two catalytic subunits named IKK α (also known as IKK1) and β (also known as IKK2) and a noncatalytic regulatory component named NEMO (NF- κ B essential modulator, which is also known as IKK γ) [7–9]. Intriguingly, genetic studies targeting each of the IKK complex subunits have delineated two mechanistically distinct pathways leading to the activation of separate NF- κ B proteins that regulate discrete panels of target genes and physiological responses [3,7–9].

By far the best studied of these mechanisms is “classical” NF- κ B signaling and it is this pathway that is rapidly and transiently activated by most known NF- κ B inducers, including the pro-inflammatory cytokines tumor necrosis factor (TNF) and interleukin 1 (IL-1), as well as engagement of innate [that is the Toll-like receptors (TLRs)] and adaptive [the T cell receptor (TCR) and the B cell receptor (BCR)] immune receptors (Fig. 2) [2,9]. Classical NF- κ B activation requires signal-induced, site-specific phosphorylation of I κ B α on two serine residues (S32 and S36 in human I κ B α) in its NH₂-terminus. This phosphorylation triggers the subsequent ubiquitination and proteasomal degradation of I κ B α , releasing NF- κ B proteins from their cytoplasmic retention. The most abundant NF- κ B species activated in this manner are p50:p65 heterodimers that are complexed with I κ B α in most cell types and are rapidly activated following stimulation. In addition to I κ B α phosphorylation, classical pathway activation also requires phosphorylation of p65 (Fig. 2) and several kinases mediate this, including IKK β , the protein kinase A (PKA) catalytic subunit, mitogen- and stress-activated protein kinase (MSK), and casein kinase 2 (CK2) [53–56]. Phosphorylation of p65 is absolutely critical for its transcriptional activity because phosphorylation allows p65 to interact with transcriptional cofactors, such as the histone acetyltransferases CBP or p300, collectively referred to as CBP/p300 [56]. Classical NF- κ B activity regulates the expression of many genes involved in immune, inflammatory, and survival responses, including those encoding cytokines (for example, IL-1, IL-2, IL-6, TNF), chemokines (for example, CXCL8, CCL2, CCL3), leukocyte adhesion molecules (for example, E-selectin, ICAM-1, and VCAM-1), and

antiapoptotic proteins (for example, Bcl2, Bcl-X_L, XIAP). Expression of these genes is normally tightly regulated by the transient kinetics of classical NF- κ B signaling [2]. However, dysregulated aberrant NF- κ B activity in diseases such as chronic inflammation and cancer leads to sustained expression of classical pathway-dependent genes and underlies the pathophysiological role of classical NF- κ B in these conditions [4,5].

Studies with cells lacking each of the IKK complex components have established a model for classical NF- κ B signaling in response to most stimuli that is dependent upon IKK β and NEMO (Fig. 2) [57–61]. IKK β is the catalytic component of the IKK complex that directly phosphorylates I κ B α leading to its ubiquitin-dependent degradation [59]. However, certain inducers including RANK-L (receptor activator of NF- κ B ligand) and IL-1 can activate the classical pathway in the absence of IKK β , suggesting that IKK α and NEMO may in fact transduce a subset of classical signals [62,63]. NEMO is absolutely crucial for all classical NF- κ B signaling and cells lacking NEMO fail to respond to any inducers of the classical pathway [60,61]. Within the IKK holocomplex NEMO associates with both IKK subunits at a small region within their COOH-termini named the NEMO binding domain (NBD), suggesting that NEMO regulates the activity of each of the IKKs [64,65]. Precisely how NEMO functions remains unclear; however, through a ubiquitin-binding domain (UBD), NEMO interacts with Lys⁶³-ubiquitinated adaptor proteins in several pathways [66,67]. This interaction recruits the IKKs to receptor adaptor complexes where they may be activated by upstream kinases or by proximity-induced trans-autophosphorylation. NEMO also oligomerizes through a minimal oligomerization domain and this is critical for signal-induced activation of the IKK complex in the classical pathway [24,68–71]. The precise role of oligomerization is not known but it is possible that it facilitates crosstalk between separate IKK subunits brought into close proximity by NEMO-NEMO interactions.

In contrast to classical NF- κ B signaling, the second NF- κ B pathway does not require either IKK β or NEMO. This mechanism is named the alternative or noncanonical pathway and is dependent on IKK α (Fig. 2) [72–75]. The noncanonical NF- κ B pathway only targets p100:RelB heterodimers which are maintained inactive by the I κ B-like COOH-terminus of p100 [75]. IKK α is the key effector kinase in the noncanonical pathway where it specifically phosphorylates the p100 COOH-terminus inducing ubiquitin-dependent proteasomal processing to p52. A second kinase upstream of IKK α named NIK (NF- κ B-inducing kinase) that phosphorylates and activates IKK α [76–78] is also critical for noncanonical signaling, and p100 processing is absent in alymphoplasia mice that carry a mutated NIK gene (NIK^{aly/aly}) [77,78]. In resting cells NIK is rapidly turned over through ubiquitination by TRAF3, which causes NIK degradation [79]. Activation of noncanonical pathway-inducing receptors sequesters TRAF3 leading to increased abundance of NIK and activation of IKK α [79].

The noncanonical pathway is activated by a subset of TNF receptor family members, including the lymphotoxin- β receptor (LT β R), CD40, RANK, and BAFF-R (B cell-activating factor receptor) (Fig. 2, right). Most stimuli that activate the classical pathway (such as TNF, IL-1, TCR, BCR) do not activate noncanonical signaling, whereas activation of LT β R, CD40, RANK, or BAFF-R can activate either the non-canonical or the classical mechanism. The major functions of noncanonical NF- κ B signaling are regulation of B cell survival and maturation and peripheral lymphoid organogenesis [72,75], and mice lacking each of the components of the pathway (NIK, IKK α , p100 or RelB) exhibit profound defects in these developmental processes [7]. Reflecting these functions, the few genes that are confirmed targets of p52:RelB are BAFF, the ligand for BAFF-R, and the chemokines CXCL12, CXCL13, CCL19, and CCL21, which function during lymphoid organogenesis [7,72,74,75].

In summary, NEMO and IKK β are required for classical NF- κ B activation in response to most inducers of this pathway. In contrast, neither NEMO nor IKK β function in the noncanonical

pathway, which depends on NIK and IKK α (Fig. 2). Because the classical pathway has critical roles in regulating immune and inflammatory responses, as well as cell survival, it is a highly promising target for the development of drugs aimed at blocking the detrimental role of NF- κ B in diseases, such as chronic inflammation and cancer. CPP-Is specifically targeting the classical NF- κ B pathway have been developed (Fig. 3) and are effective *in vitro* and, in some cases, *in vivo* using animal models of disease.

To date peptide transduction approaches have only been applied to studies of the classical pathway and the genes and pathophysiological responses it regulates. However, given the potential clinical importance of developing NF- κ B pathway-specific blocking strategies, we anticipate that noncanonical pathway-targeting CPP-Is will emerge in the near future. The CPP-Is discussed in detail in the following sections were specifically developed to block classical signaling by either disrupting the IKK complex or by inhibiting critical events downstream of IKK β (Table 2; Fig. 3). In addition, several peptides that target upstream intermediates in the NF- κ B pathway or other signaling mechanisms, such as the ERK and JNK pathways, have also been developed. These IKK-proximal CPP-Is are described briefly.

CPP-Is targeting IKK-proximal signaling

Several CPP-linked peptide inhibitors of NF- κ B signaling that function upstream of IKK complex activation have been described. One group of these peptides directly targets the TLR / IL-1 family of innate immune receptors or their immediately distal adaptor proteins. In a recent report, Toshchakov and co-workers generated three separate AntP fused peptides spanning the highly conserved BB loops within the TIR (Toll-interleukin 1 receptor) domains in the cytoplasmic tails of TLRs 1, 2, 4 and 6 [80]. BB loops are the docking sites for downstream adaptor proteins and, consistent with this, the TLR2- and TLR4-BB peptides blocked NF- κ B activation in macrophages in response to LPS and two lipopeptides (P2C and P3C). Intriguingly however, although TLRs 1 and 6 form heterodimers with TLR2, a peptide spanning the identical BB domains in these receptors (TLR1/6-BB) did not block NF- κ B signaling in response to any agonist. These findings therefore revealed distinct but as yet unclear roles for the TLR- BB domains in regulating the unique signaling functions of these individual receptors [80].

Two separate CPP-Is targeting adaptor proteins that associate with the TLR / IL-1 receptor family have also been described. The first of these is a peptide directed against TIR domain-containing adaptor protein (TIRAP) that is recruited to TLR4 following LPS stimulation [81]. Horng and colleagues demonstrated that a fusion of the TLR4 interaction domain of TIRAP with AntP (AntP-TIRAP) blocked LPS-induced NF- κ B activation in a murine monocytic cell line and primary dendritic cells [81]. AntP-TIRAP has also been shown to function *in vivo*, where it blocked LPS-induced innate immune responses in the lungs of mice [82]. Importantly, although AntP-TIRAP effectively blocked LPS signaling, it had no effect on TLR9-induced NF- κ B activation [81]. This therefore demonstrates that selective targeting of receptor-specific adaptor proteins using CPP-Is can be used to block NF- κ B activation in a pathway-specific manner.

The second CPP-I targeting TLR / IL-1 receptor signaling adaptor proteins was derived from the BB sequence within the TIR domain of MyD88 [83]. Loiarro and co-workers demonstrated that an AntP chimera of this peptide could enter HeLa and HEK293 cells, inhibit MyD88 homodimerization and block IL-1-induced NF- κ B [83]. Intriguingly, this group more recently reported that a synthetic peptidomimetic compound (ST2825) modeled on the same BB sequence of MyD88 also blocks IL-1-induced MyD88 homodimerization, IRAK1 and IRAK4 recruitment and NF- κ B activation in HeLa cells [84]. Remarkably, oral administration of ST2825 significantly decreased serum levels of IL-6 in mice injected intraperitoneally with IL-1. These findings therefore support the concept that targeting specific signaling events by

CPP-Is provides the rationale for the development of further generations of potentially important therapeutic compounds.

Another group of IKK-proximal CPP-Is that block NF- κ B activation targets the signaling intermediate TRAF6. TRAF6 functions in multiple pathways including those induced by RANK-1 and CD40 and CPP-Is that block its association with these receptors have been reported [85,86]. The first of these peptides was derived from the TRAF6 interacting motif in RANK-1 fused with MTS and was named the TRAF6 decoy peptide (L-T6DP-1) [86]. L-T6DP-1 blocked RANK ligand (RANKL)-induced NF- κ B activation in macrophages whereas an MTS-fusion peptide encompassing the similar region in RANK-2 (L-T6DP-2) did not. This is consistent with the lower affinity of TRAF6 for RANK-2 and confirms the specificity of the effects of these separate CPP-Is.

Further studies with L-T6DP-1 verified the importance of the RANK-TRAF6 interaction for a number of RANKL-induced responses including osteoclastogenesis *in vitro* [86], HIV induction in PBMCs [87] and growth inhibition of monocytes [88]. Using a similar approach Mukundan et al. [85] demonstrated that a CPP-I consisting of MTS and the TRAF6 interaction domain of CD40 blocks CD40L-induced IL-1 β , TNF and IL-6 expression in elutriated primary human monocytes. In contrast this peptide did not inhibit PMA-induced pro-inflammatory cytokine expression in monocytes: a response that bypasses the requirement for TRAF6.

Although each of these IKK-proximal CPP-Is was shown to block NF- κ B activation, none were absolutely specific for the NF- κ B pathway. This is not surprising as these peptides were developed to target signaling intermediates that function upstream of multiple mechanisms. Consistent with this, these CPP-Is inhibit other receptor-induced signals including those activating PKR, JNK and ERK1/2. Nevertheless, these reagents have allowed investigators to directly interrogate the importance of the molecular interactions that these peptides target. As a result, the demonstrated *in vivo* efficacy of some of the CPP-Is confirms the therapeutic relevance of disrupting these crucial signaling mechanisms. These CPP-Is have also revealed important, and in some cases unexpected, molecular insight into the signaling events that they disrupt making them valuable new weapons in the arsenal of target-specific inhibitors available for signaling research.

We will focus the remainder of our discussion on the CPP-Is specifically designed to target key interactions or signaling events at, or downstream of, the IKK complex. These inhibitors and their targets are described in Table 2 and the positions within the classical NF- κ B signaling cascade that they target are depicted in Figure 3.

CPP inhibitors of NF- κ B nuclear localization

In 1995, Jacek Hawiger and colleagues were first to describe a CPP-I specifically designed to block NF- κ B activation [26]. The CPP-I they developed contained the nuclear localization sequence (NLS) of p50 (N50: VQRKRQKLMP) preceded by MTS (the hydro-phobic signal peptide CPP) and was termed SN50 for signal peptide:NLS of p50. This peptide functioned by blocking the nuclear translocation of NF- κ B. In contrast, a version of the peptide containing a mutated NLS sequence (VQRNGQKLMP; mutated residues in bold italics) had no effect. In addition to being the first CPP-I directed against NF- κ B signaling, SN50 was also the first intensely utilized CPP-linked inhibitor of any signaling pathway. In this regard, the initial studies of SN50 defined the field of signal-directed CPP-I transduction. In the original manuscript, a ¹²⁵I labeled SN50 peptide was used to verify its cell permeability [26] providing the first direct evidence of the feasibility of this approach for delivering bioactive cargo targeting the NF- κ B pathway. SN50 provided an exciting new reagent to probe the biological relevance of NF- κ B activation and it was shown to dose-dependently inhibit LPS- and TNF-induced nuclear translocation of NF- κ B in a range of cell types including fibroblasts,

monocytes and vascular endothelial cells. Importantly, signal-induced I κ B α degradation remained intact in SN50-treated cells, demonstrating that the peptide specifically blocked the nuclear transport of NF- κ B [26]. Many later studies have added to the extensive list of stimuli whose responses are blocked by SN50 and the cell types in which it has been effectively utilized (see below).

The mechanism by which SN50 inhibits NF- κ B nuclear localization has been resolved. The p50 NLS interacts with a nuclear transport localization complex that includes the importin- α (Rch1/Karyopherin- α 2)/importin- β heterodimer [89]. The importin complex exists in the cytoplasm and at nuclear pores and facilitates the entry of the protein being carried through the pore. Typically NLS sequences bind to importin- α , are targeted to the nuclear pore by importin- β , freed from importin- β and translocated into the nucleus with importin- α in an energy-dependent step mediated by Ran GTPase [90]. SN50 prevents this system from transporting NF- κ B p50 by competing with the importin complex for p50 [89]. As a result, the importin complex is occupied by SN50 leaving p50 in the cytoplasm.

As SN50 blocks p50 translocation by binding the importin complex, it is not surprising that it was found in later studies to inhibit nuclear entry of other transcription factors that utilize importin [41,89]. In particular, PMA/ionomycin- and IFN- γ -induced nuclear translocation of AP-1, NFAT and STAT-1 in Jurkat T cells was shown to be inhibited by SN50 [89]. This blockade resulted in abrogation of IL-2 mRNA synthesis, a process that depends upon AP-1 and NFAT in addition to NF- κ B. Mutant SN50 peptides containing an altered NLS are not able to bind to importin and failed to inhibit the translocation of any of these transcription factors. Separate studies using primary human lymphocytes did show that at low doses, SN50 specifically blocked NF- κ B without inhibiting AP-1 and NFAT [91]. However, in light of its effects on multiple transcription factors, SN50 has more recently been defined as an inhibitor of the general stress-responsive transcription factor (STRF) program [92–94]. But despite these obvious specificity issues, SN50 remains a widely used reagent in studies of NF- κ B function *in vitro* and *in vivo*. Over two hundred peer-reviewed articles have reported the utility of SN50 in this capacity, although clearly its potential effects on other transcriptional mechanisms must be very carefully considered when interpreting the results of these studies [92,95].

Some of the most intriguing reports of SN50 function have been in the field of neuroscience and include the demonstration that nerve growth factor serves as a sympathetic neuronal survival factor *in vivo* [96]. Similarly, SN50 was used to demonstrate that nerve growth factor can induce apoptosis when it is unable to provide physiologic stimulation of NF- κ B activation [97]. *In vivo* SN50 was used to show that dopamine-[98], NMDA receptor- [99], or AMPA receptor-induced [100] apoptosis of rat striatal neurons requires NF- κ B function. Thus, SN50 has served as a very useful tool for dissecting the pro- and anti-apoptotic roles of NF- κ B in neuronal cells and these accumulated data suggest that an NF- κ B targeted CPP-I approach may hold promise in neurodegenerative diseases characterized by excessive neuronal apoptosis.

SN50 has also been used extensively to demonstrate the requirement for dysregulated NF- κ B activity in the survival and proliferation of cancer cells. As an example, the peptide induces apoptosis in multiple myeloma (MM) cell lines as well as *ex vivo* MM cells from patients with active disease [101]. Further evidence supporting the efficacy of SN50 *in vivo* comes from studies of LPS-induced endotoxic shock in mice in which intraperitoneal injection of a cyclic version of the peptide (cSN50) effectively blocked pro-inflammatory cytokine production and lethality [94]. In addition, cSN50 prevented liver apoptosis and hemorrhagic necrosis in LPS-treated mice that may be due in part to the inhibition of expression of pro-apoptotic proteins such as Bax [93]. While these findings suggest that inhibition of NF- κ B is critical for the observed effects, it is more likely that the overall efficacy of cSN50 is due to its ability to block multiple SRTFs. Nevertheless these studies add strong support to the potential therapeutic

application of CPP-Is based on the p50 NLS for directly inhibiting nuclear translocation *in vivo*.

Since the discovery of SN50, at least five other CPP-Is directed against NLSs have been developed and used to block NF- κ B nuclear translocation. The first of these use the same CPP and NLS sequences, but are ligated via a thiazolidino linkage [41]. These CPP-Is, termed ScN50A and ScN50B, worked at least as well as SN50 in blocking NF- κ B translocation in PMA/ionomycin-stimulated Jukat cells but similar to SN50 they also blocked the translocation of NFAT and AP-1. Another CPP-I targeting the p50 NLS uses AntP in place of MTS as the transduction sequence. This peptide is termed PN50 (for Penetratin NLS of p50) and has been shown to reduce TNF-induced NF- κ B activity in fibroblasts. *In vivo*, PN50 reduces NF- κ B activation and improves pancreatitis induced by cholecystokinin in mice, a model in which NF- κ B activity directly correlates with severity of disease [102]. Similar to SN50 it is presumed that PN50 will inhibit the nuclear localization of other transcription factors as it contains the p50 NLS. This, however, has not yet been reported.

The second series of novel NLS-targeting CPP-Is also use MTS, but derive their cargo from c-myc or SV40 [103]. Both of these peptides consist of the MTS flanked on either side by the respective NLS: PKKKRKV for the SV40 construct (named BMS-205820) and AKRVKL for the c-myc construct (named BMS-214572). The reason for using two NLSs was the discovery that a single molecule of importin- α binds 2 NLS sequences [103]. Thus, the dual NLS based CPP-Is were hypothesized to be more potent and were in fact 35-fold more active than SN50 in some experiments [104]. Both BMS-205820 and BMS-214572 prevent LPS induced NF- κ B translocation and IL-6 production and encouragingly, these peptides are more specific for NF- κ B than SN50, as they do not affect the nuclear translocation of NFAT under identical conditions. BMS-205820 has also been tested *in vivo* and found to significantly enhance survival in murine LPS-induced shock, and it reduces the severity of disease in murine DSS-induced inflammatory bowel disease [104].

The NEMO binding domain (NBD) peptide

The central role of the IKK complex for NF- κ B signaling makes it an attractive target for the development of NF- κ B-specific drugs or blocking reagents. While most pharmaceutical companies focus on developing IKK-specific inhibitory compounds [5,6], the role of NEMO as the critical regulatory subunit has not escaped the attention of researchers seeking to manipulate the IKK complex. In this regard, three CPP-Is have been developed that directly target NEMO: the NEMO-binding domain peptide that we will describe here, and more recently, two peptides that block NEMO oligomerization that we will discuss in the following section.

Early studies of the IKK complex suggested that NEMO interacts only with IKK β [105] and mutational analysis revealed a six amino acid segment (L737 to L742: LDWSWL) within the extreme COOH-terminus of the kinase that was absolutely necessary for NEMO binding (Fig. 4) [64,65]. More recent studies indicate that a slightly larger region encompassing residues T735 to E745 represents the full domain required for NEMO-association [106–108]. This region was named the NEMO binding domain (NBD) and substitution of the tryptophan residues (W739 and W741) with alanine prevented the interaction with NEMO [64, 65]. Remarkably, the identical core of six amino acids are also present in the COOH-terminus of IKK α (Fig. 4) and NEMO in fact associates with IKK α via this functional NBD [64,65]. Subsequent studies have verified the association of NEMO with both IKKs, although the role of NEMO in regulating the function of IKK α remains somewhat obscure [63,109].

Initial biochemical analysis using GST pull-down assays demonstrated that a peptide spanning the NBD could block NEMO binding to both IKKs [64]. In contrast, a peptide containing the

tryptophan mutations (Fig. 4) failed to block, thereby demonstrating the requirement for the intact domain. Intriguingly, these *in vitro* studies also revealed that the affinity of IKK β for NEMO was slightly higher than that of IKK α , possibly accounting for the previous failure of others to detect the association with IKK α [105]. To determine whether this NBD spanning region could affect signaling in cells, an AntP fusion peptide was generated and used to transduce HeLa Cells [64]. This peptide effectively blocked TNF-induced IKK and NF- κ B activation but did not affect c-jun phosphorylation, demonstrating both the cellular delivery of the peptide and its specificity for NF- κ B signaling.

The AntP version of the NBD peptide and the inactive mutant control (Fig. 4) have been used extensively to block NF- κ B in a wide range of cellular and *in vivo* studies. A number of recent reports have also demonstrated the successful transduction of the NBD sequence into several different cell types and *in vivo* using both TAT and PTD-5, demonstrating that the CPP used for delivering the NBD is interchangeable [25,38,110–114]. Furthermore, recent pharmacological data comparing the NBD peptide delivered by AntP and TAT demonstrated that neither CPP-NBD combination is cytotoxic within their effective dose ranges, although both TAT- and AntP-NBD exhibit significant cytotoxicity at higher doses [37,38]. In a separate study PTD-5-NBD was also found to be non-toxic and it actually rescued pancreatic islet cells from IL-1 β -induced cell death [111]. Thus, regardless of the CPP used to deliver the sequence, doses of the NBD that effectively block NF- κ B activation are non-toxic *in vivo* and in the majority of cell types so far examined.

Below we will highlight reports in which the NBD has been applied to cellular studies of NF- κ B in inflammation, infection and immunity, cancer, cellular stress and cytoprotection. We will conclude this section by describing how the NBD peptide has been utilized *in vivo* in relevant animals models of disease.

Inflammation

The best characterized NF- κ B activation pathways are those elicited by the pro-inflammatory cytokines TNF and IL-1 that function via the classical mechanism [2,7]. The dependence on NEMO for classical NF- κ B-induced gene expression led a number of groups to use the NBD peptide to block cytokine-induced NF- κ B in cell culture models including HeLa cells [64, 115]. The first evidence of disease relevant signal inhibition came with the original description of the NBD peptide in which it demonstrated effective blockade of TNF-induced expression of the leukocyte adhesion molecule E-selectin by human umbilical vein endothelial cells [64]. Subsequent studies in endothelial cells also demonstrated that the NBD blocks TNF- and thrombin-induced expression of the store-operated calcium channel TRPC, thereby preventing augmented Ca²⁺ entry and TNF-induced endothelial cell injury [116,117]. The effect of NBD blockade on IL-1 signaling has more recently been confirmed by Fukushima and colleagues, who demonstrated inhibition of IL-1 induced I κ B α degradation in periodontal ligament cells [118]. Furthermore, as part of an *in vivo* study of IL-1-induced brain inflammation Nadjar et al. showed that the NBD peptide blocks IL-1—induced p65 translocation in rat glioma cells [119].

Studies of other pro-inflammatory mediators have further established the ability of the NBD peptide to block NF- κ B activation and pro-inflammatory gene expression. In this regard, the NBD was shown recently to inhibit NF- κ B and chemokine expression in pancreatic acinar cells incubated with substance P, a neuropeptide that plays an important role in the pathogenesis of acute pancreatitis and certain other inflammatory diseases [120]. The NBD has also been effectively used to block NF- κ B induced by the TNF family member RANKL and studies of bone destruction in inflammatory diseases have demonstrated inhibition of RANKL-induced NF- κ B activation in osteoclasts [88,113,114,121]. Using the AntP version of NBD, Jimi et al. demonstrated inhibition of RANKL-induced osteoclastogenesis *in vitro* [121] and similar

effects were reported by Dai and colleagues using a TAT-NBD peptide [113]. This group also demonstrated that TAT-NBD blocks NF- κ B activation in osteoclast progenitors and *in vitro* osteoglasto-genesis induced by PMMA particles [114]. Together with the *in vivo* data generated in each of these studies (discussed below), these findings clearly demonstrate that the NBD peptide is an effective blocker of both acute and chronic inflammatory signaling in a wide range of cell types and cellular models of inflammatory disease.

Infection and immunity

NF- κ B activation has been intensely studied in the context of infection and immunity, where it functions in both innate immune activation and the development and activation of the adaptive immune response. The recent wealth of knowledge concerning innate immune activation and, in particular, signaling via the TLR family of receptors has led to an upsurge of interest in the role of NF- κ B in regulating these events. Due to the crucial role of classical NF- κ B in innate immune recognition of bacterial and viral antigens, as well as in dendritic cell activation and lymphocyte development, the NBD peptide has been used in a host of *in vitro* studies of infection, TLR signaling and immune cell activation.

In studies dissecting the role of NF- κ B activation in regulating innate immune responses to pathogens, the NBD peptide has been reported to block signaling and gene expression in cells incubated with the parasites *Theileria parva* and *Trypanosoma cruzi* [122,123], the bacteria *Escherichia coli*, *Streptococcus pneumoniae*, *Legionella pneumophila* and *Moraxella catarrhalis*, [124–128], and the single stranded negative sense RNA virus of the *Paramyxoviridae* family, *Respiratory syncytial virus* (RSV) [129]. In addition, the NBD peptide inhibited NF- κ B-dependent gene expression in cells stimulated with bacterial toxins including vacuolating cytotoxin (VacA) from *Helicobacter pylori* [130] and *Clostridium difficile* toxin A [131]. The ability of the peptide to inhibit TLR signaling was first demonstrated in macrophages in which the NBD blocked LPS-induced nitric oxide production most likely via inhibition of iNOS expression [64]. Subsequent work from Choi et al. showed that TAT-NBD completely inhibited LPS-stimulated IKK activation, NF- κ B activity and gene expression in neutrophils [110]. Separate studies of TLR signaling have confirmed that the NBD peptide effectively blocks innate-immune NF- κ B activation and responses including chemokine expression [132,133], upregulation of TLR2 surface expression [134], induction of anti-apoptotic genes [135], upregulation of integrin expression [136] and induction of the intestinal epithelial cell-derived cytokine thymic stromal lymphopoietin (TSLP) [137].

A number of studies have utilized the NBD peptide to examine adaptive immune cell activation and it has been reported to be effective in several models of T cell activation and development. Incubation of T cells with the peptide inhibits TCR-induced NF- κ B activation [138,139] and blocks induction of the trans-activating I κ B-like protein Bcl3 which, in turn, affects the generation of Th1 effector T cells [140]. Two studies have also demonstrated inhibition of anti-apoptotic gene expression in T cells and enhanced cell death in response to TLR [135] or TCR [138] stimulation supporting a key role of IKK/NF- κ B signaling in lymphocyte development. Elegant *ex vivo* differentiation studies by Igarashi et al. further demonstrated that the NBD peptide blocks B and NK cell development from bone marrow cells in culture by preventing their ability to resist TNF-mediated inhibitory effects [141]. Separately, the peptide was reported to enhance apoptosis in B cells and block the protective effects of BCR-activated Bcl10 on B cell survival [142]. Intriguingly, inhibition of NF- κ B in dendritic cells (DCs) by the NBD peptide blocks the expression of IL-6, IL-12 and TNF and significantly affects T cell proliferation and Th1/Th2 polarization in allogeneic mixed lymphocyte cultures [143]. Additional studies in which DCs were activated following cytokine withdrawal by cross-linking cell surface B7-DC with a specific IgM antibody demonstrated that cell survival was dependent upon NF- κ B as treatment with the NBD peptide led to enhanced apoptosis [144].

These studies therefore identify the NBD peptide as a powerful tool for the manipulation of the IKK complex in DCs, T and B cells *in vitro*. As we will discuss below, evidence for the efficacy of the NBD peptide in blocking adaptive immune responses *in vivo* in models of chronic immune-mediated inflammation is also beginning to emerge [145].

Cancer

A number of *in vitro* studies utilizing the NBD peptide have focused on its ability to block aberrant NF- κ B activity in a range of cancer cell lines. The role of constitutively active NF- κ B in certain types of cancer cells has been the subject of intense scrutiny over the last few years since it was found to regulate anti-apoptotic and cell survival genes that rescue cancer cells from exogenous apoptotic stimuli. This allows these tumor cells to survive and proliferate and it is now well recognized that inhibition of NF- κ B renders such cells sensitive to apoptotic cell death [4,146]. Most of these inhibition studies have employed nonselective inhibitors of NF- κ B; the NBD peptide, however, has verified the role of NEMO-dependent IKK activity in some tumor cells and has been shown to effectively block dysregulated NF- κ B in a variety of cell-based models of cancer.

The effects of the NBD peptide on tumor cells were first reported in the human breast carcinoma cell line MCF-7 that is rendered susceptible to TRAIL- or TNF-induced apoptosis following NBD treatment [147–149]. Similar studies of pancreatic and colon adenocarcinoma cells also demonstrated sensitization to TRAIL [149,150] and the NBD was reported to block proliferation and induce apoptosis in human breast cancer cell specimens [151,152]. In addition to rendering tumor cells susceptible to exogenously applied apoptotic stimuli, the NBD peptide also inhibits the basal proliferation and survival of several tumor cells including multiple myeloma [153], Hodg-kin's lymphoma [154], pancreatic cancer [155] and head and neck squamous cell carcinoma [156]. In each of these studies, the effects of the NBD peptide have been correlated with inhibition of NF- κ B activity and subsequent reduced proliferation, increased cell death or downregulation of anti-apoptotic and pro-survival gene expression.

NF- κ B also plays a critical role in the resistance of some tumors to anti-cancer drugs that induce anti-apoptotic genes and promote cell survival instead of killing the target tumor cells [4]. The NBD peptide has been used in this regard to block drug-induced NF- κ B activation and has been shown to inhibit IKK and NF- κ B activation by the microtubule depolymerizing agent nocodazole [157]. This blockade led to enhanced apoptosis in the nocodazole-treated cells. Some genotoxic anti-cancer drugs such as the topoisomerase II inhibitor etoposide (VP16) also activate NF- κ B, leading to cancer cell survival and, in a recent study by Shigeki Miyamoto's group, the NBD peptide inhibited VP16-induced NF- κ B activation [158]. However, not all NF- κ B activation by anti-cancer drugs leads to cell survival and the cytotoxic effects of the antibiotic doxorubicin and its analogues are thought to depend upon NF- κ B activation. This cytotoxic role for NF- κ B was supported by recent evidence that the NBD peptide suppressed doxorubicin-induced cytotoxicity in myeloid and lymphoid tumor cells [159]. It is clear therefore that the NBD peptide is a useful reagent for experimentally dissecting the precise effects of anticancer drugs on tumor cells and it may also represent a realistic candidate for adjunct therapy aimed at improving the efficacy of some of these drugs.

Cell stress, cytoprotection and cell survival

In addition to cancer cell survival, NF- κ B activity also plays a pivotal role in the cytoprotection and survival of normal cells in the face of a wide variety of cellular stresses. In this regard the NBD peptide has been shown to block NF- κ B-dependent cell survival in a range of cell types exposed to distinct cellular stresses. For example the stress-induced IL-6 family cytokine cardiotrophin-1 (CT-1) that is released during hypoxia, activates NF- κ B in cardiac myocytes and promotes their survival. The NBD peptide blocks CT-1-induced survival demonstrating

the key role of NF- κ B in this cytoprotective response [160]. The NBD peptide also causes apoptosis in activated hepatic stellate cells (HSC) supporting a role for NF- κ B activation in HSC proliferation and pro-fibrotic function following liver injury [161]. In a study of the effects of ethanol on rat gastric mucosal epithelial cells, the NBD was shown recently to block ethanol-induced NF- κ B and COX-2 expression and enhance apoptosis [162]. Finally, studies in neutrophils have revealed that TAT-NBD blocks TNF-induced cell survival after heat injury, again demonstrating a pro-survival role for NF- κ B in response to exogenous stress [112].

***in vivo* studies of the NBD peptide**

The NBD peptide was originally shown to be effective *in vivo* in two models of acute inflammation [64]. The first of these was a mouse model of zymosan-induced peritonitis hallmarked by rapidly enhanced neutrophil infiltration and increased peritoneal exudate volume. In this model, intraperitoneal injection of the NBD peptide blocked inflammation by inhibiting both of these parameters. In the same study topical application of the peptide blocked PMA-induced ear edema, again demonstrating the ability of the peptide to inhibit local acute inflammatory reactions. These two experiments not only established the *in vivo* efficacy of the NBD peptide but they also demonstrated its ability to be successfully delivered via separate routes of administration (i. p. and topical). Following this initial description, the anti-inflammatory activity of the NBD was further established in mice in a carrageenan-induced paw edema model of acute inflammation [163]. In this study, the wild type peptide effectively reduced footpad swelling whereas the mutant had no effect. Biochemical and molecular analysis further revealed inhibition of NF- κ B and significant reduction of COX-2 and TNF expression in paw tissue from the animals injected with wild-type NBD [163]. In a study of cerulein-induced acute pancreatitis, Ethridge et al. demonstrated that i. p. injection of the NBD ameliorated the resulting inflammation by reducing edema, hemorrhage and neutrophil influx [164]. Three recent reports have also demonstrated the effectiveness of the NBD peptide in blocking inflammation-induced bowel injury [165,166]. In the first of these studies, De Plaen et al. investigated the role of NF- κ B in regulating the profound intestinal injury observed in a rat model of neonatal necrotizing enterocolitis (NEC) [165]. Consistent with a major role for aberrant NF- κ B signaling in NEC, the wild-type but not mutant NBD peptide decreased mortality and significantly ameliorated bowel injury in this model [165]. In the second study Shibata and colleagues employed two mouse models of colitis (dextran sulfate sodium salt [DSS] in the drinking water and trinitrobenzene sulfonic acid enema) that are hallmarked by increased NF- κ B activity and pro-inflammatory cytokine expression in inflamed intestinal tissue [166]. In both of these models the NBD peptide inhibited NF- κ B activation, blocked increased cytokine expression and prevented inflammatory injury. In the third model, Dave et al. explored the effects of the NBD peptide in a model of spontaneous chronic murine colitis in mice lacking IL-10 [167]. Using a version of the NBD fused with 8K as the CPP these workers demonstrated that 8K-NBD ameliorated colitis, inhibited NF- κ B activation in the lamina propria, and blocked expression of pro-inflammatory cytokines in the intestine.

The NBD peptide has also been applied to investigations of the pathological role of NF- κ B in lung inflammation. Haeberle and colleagues demonstrated that intra-nasal administration of the peptide inhibits acute inflammation in the lungs of mice infected with RSV [129]. In this study the peptide inhibited NF- κ B activity in infected lungs and ablated RSV-induced chemokine expression and inflammation-associated pathology. More recently, Chapoval et al. showed that the peptide reduced IL-13-induced tissue inflammation, fibrosis and alveolar remodeling in an IL-13-transgenic mouse model of asthma [168]. In separate studies, topical nasal administration of the NBD peptide in piglets inhibited severe inflammation induced by repeated airway lavage [169,170]. In this model of acute respiratory distress syndrome the peptide significantly reduced lung edema, protein content in the epithelial lining fluid, PMN accumulation and leukotriene B4 levels and improved the functional residual capacity, alveolar

volume and lung mechanics [169,170]. Importantly, in addition to verifying the ability of the NBD peptide to ameliorate lung inflammation, these studies are the first to establish its efficacy in large animal models of disease. Consistent with the ability of CPPs to deliver functional protein and peptide cargos across the blood-brain barrier [48–50,171], the NBD-peptide enters the brain and inhibits NF- κ B in models of inflammation and injury. In this regard, Nadjar and colleagues have established that intraperitoneal as well as intra-cranial injection of the NBD peptide effectively blocks IL-1-induced NF- κ B activation and COX2 expression in brain microvascular endothelial cells and ameliorates sickness behavior in rats [119,172]. In a separate study, it was also shown that intraperitoneal injection of the NBD peptide up to 12 hours after reoxygenation following hypoxia/ischemia (HI)-induced cerebral damage inhibited NF- κ B activity in rat brain tissue [173]. Intriguingly however, NF- κ B inhibition after reoxygenation enhanced the brain damage observed six weeks after HI [173]. More recent studies have demonstrated that the timing of administration of the NBD peptide in this model is absolutely critical and that treatment of rats either immediately or up to six hours after HI leads to almost complete inhibition of the brain damage observed six weeks later [174,175]. The NBD peptide has also shown promising efficacy in a mouse model of Parkinsons disease (PD) in which it prevented nigro-striatal degeneration and dopaminergic neuron loss [176]. In this model, intraperitoneal injection of the peptide inhibited NF- κ B activation and blocked pro-inflammatory cytokine expression in the brains of experimental mice. Moreover, NBD-treated mice exhibited improved activity levels and motor functions, strongly suggesting that NF- κ B-induced inflammation contributes to PD and is thereby a viable therapeutic target.

The ability of the NBD peptide to inhibit chronic inflammation has also been demonstrated. In two separate reports, the peptide inhibited collagen-induced arthritis in mice by blocking *in vivo* NF- κ B activation in osteoclasts, resulting in reduced osteoclastogenesis and focal bone erosion [113,121]. Systemic application of the peptide in these studies also reduced lymphocyte infiltration and chronic inflammatory pathology in the joints. Similar inhibition of synovial inflammation by the peptide was also demonstrated in a model of adjuvant arthritis in rats [177]. Further evidence for the efficacy of the NBD against inflammation-induced bone loss emerged from a study of osteoclastogenesis and calvarial inflammatory osteolysis in response to poly(methyl methacrylate) (PMMA) particles [114]. In this murine model of implant failure at the bone implant interface, subperiosteal injection of the TAT-NBD peptide over the calvaria abrogated PMMA-induced inflammation and osteolysis.

The NBD peptide has been studied in the context of chronic inflammation of the CNS in an adoptive transfer model of experimental allergic encephalo-myelitis. In this model the clinical symptoms of EAE were significantly reduced in wild-type NBD injected (i. p. / alternate days for >50 days) compared with mutant-injected or control animals [145]. This reduction of symptoms was accompanied by reduced NF- κ B activity, a shift in the immune response from a Th1 to a Th2 profile and inhibition of the MBP-specific T cell function. Furthermore, the NBD inhibited the induction of iNOS, IL-1 β and TNF in the cerebellum of the EAE animals. In a recent study, the peptide was also shown to block muscle degeneration in the *mdx* mouse model of Duchenne muscular dystrophy (DMD) [178]. These animals develop clinical symptoms similar to DMD patients including elevated pro-inflammatory cytokine levels in their muscles, persistent inflammation hallmarked by immune cell invasion, and degeneration of the diaphragm leading to early lethality. The wild-type NBD inhibited elevated NF- κ B activity in the muscles of *mdx* mice resulting in significantly reduced inflammation, muscle regeneration and improved diaphragm function [178].

Taken together these separate *in vivo* studies clearly demonstrate that the NBD peptide is effective in established models of both acute and chronic inflammation. In many of the published models, inhibition of inflammation has been correlated with the inhibition of NF- κ B in tissue and the subsequent reduction of NF- κ B-dependent pro-inflammatory gene

expression. A number of routes of administration including topical, i. p., intranasal and intracranial, have been tested and the ability of the peptide to function in each of these studies clearly demonstrates that its effects are systemic and that it can reach sites both local and distant from the original point of injection. Furthermore, in some of the studies of chronic inflammation, the NBD peptide was administered for over 50 days on each alternate day without any observable toxicity, liver damage or other detrimental side effects [121,145]. These acute and chronic inflammation studies were performed using doses of the peptides ranging from 0.75 to 20 mg / kg and, in our experience, these doses are completely tolerated by mice and rats without any observable toxicity. Evidence of toxicity and rarely also of seizure is only observed in mice when doses of over 50 mg / kg are used (unpublished observations); these effects, however, are related to the high concentration of the CPP as similar toxicity is observed with the inactive mutant control peptide or the CPPs alone.

Future applications

Due to the general lack of specificity of the NLS CPP-Is for NF- κ B, the NBD peptide is currently the best-studied highly selective cell-penetrating peptide inhibitor of classical NF- κ B signaling. As we have discussed, this CPP-I effectively inhibits NF- κ B in a wide range of cell models and more importantly, it functions *in vivo* in relevant animal models of disease. Given the number of *in vitro* studies focused on NF- κ B in cancer that have utilized the NBD, it is surprising that it has not yet been applied to any *in vivo* models of cancer. The efficacy of the peptide in animal models of acute and chronic inflammation makes this an eagerly anticipated prospect.

One outstanding question regarding the function of the NBD peptide concerns its effects on IKK α . Current dogma dictates that IKK α plays no role in classical NF- κ B signaling that requires only NEMO and IKK β [2,7–9]. Furthermore, NEMO is not thought to function in the non-canonical NF- κ B pathway that requires only IKK α . Nevertheless, it is clear that IKK α contains a functional NBD and that the NBD peptide disrupts its interaction with NEMO [63–65,109]. There is currently no known role for NEMO in regulating mammalian IKK α ; our recent findings, however, suggest that a NEMO-IKK α complex is sufficient to transduce IL-1- but not TNF-induced signaling to NF- κ B [63]. Moreover, a recent report demonstrated that IKK α in zebrafish is regulated via interaction with NEMO [109]. Intriguingly this occurs through an NBD in zebrafish IKK α that contains a very similar “core” to the mammalian domain (QDWSWT compared with LDWSWL in mammals). In the zebrafish system the NEMO-IKK α interaction plays a role in down regulating classical NF- κ B activation [109] and it is fascinating to consider such a model for the mammalian IKK complex. Recent evidence from the laboratories of Michael Karin and Inder Verma supports a negative regulatory role for IKK α in the classical pathway [179,180] and, consistent with NEMO functioning in this negative regulation, we have previously reported that the NBD peptide increases basal NF- κ B activity in HeLa and vascular endothelial cells [64]. Nevertheless, further study is required to verify this role for NEMO in basal IKK activity and we predict that the NBD peptide will be a crucial experimental tool for probing the functional relationship between IKK α and NEMO. It is clear therefore that a better understanding of the effects of the NBD peptide on both IKK β and IKK α function *in vitro* and *in vivo* is required. Indeed, such insight will be crucial if the NBD is to be considered as a potential target for the development of clinically acceptable drugs.

Other CPP inhibitors of NF- κ

CPP-Is targeting the NLS and the NBD are by far the best characterized of the current peptides specifically directed against the NF- κ B pathway. However, a number of recent studies have reported the use of peptide transduction to generate reagents that selectively target other critical components of the classical pathway. These novel CPP-Is include two peptides that block

NEMO oligomerization and a group of inhibitors that specifically interfere with the phosphorylation of p65 and I κ B α (Table 2). Although less is known about the range of effects of these CPP-Is, they have each been shown to block signal-induced NF- κ B activation and its functional activity in cells and in some cases *in vivo*. It is therefore likely that these inhibitors will become more widely used as researchers seek to selectively target NF- κ B in animal models of disease.

Inhibitors of NEMO oligomerization

NEMO oligomerization is absolutely critical for signal-induced IKK complex kinase activity [24,68–71] and two novel CPP-Is that disrupt this process were described recently [68]. Oligomerization requires both the second coiled-coil (CC2) and leucine zipper (LZ) domains of NEMO (Fig. 5) and together with the intervening linking sequence, these are named the minimal oligomerization domain (MOD). To target the MOD in mouse NEMO, Agou and colleagues designed two AntP-chimeric peptides directed against each of these regions. The first peptide consisted of the full length of CC2 (named AntP-NEMO-CC2) and the second encompassed the complete LZ domain (named AntP-NEMO-LZ) (Table 2; Fig. 5) [68]. Biophysical analysis demonstrated that both of these peptides could bind to NEMO and functional assays verified that they disrupted its oligomerization *in vitro*. Importantly, the ability of AntP-NEMO-CC2 and –LZ to block NF- κ B activity was demonstrated in LPS-stimulated 70Z/3 mouse pre-B cells whereas neither peptide inhibited p38 or ERK signaling. Agou and coworkers also generated control peptides by selectively substituting critical residues in the CC2 and LZ domains and none of these mutants disrupted NEMO oligomerization or blocked NF- κ B activation in cells [68].

Despite these extremely promising results, one issue concerning the precise mode of function of these CPP-Is remains to be resolved. Recent studies have reported that the ability of NEMO to interact with upstream K63-linked polyubiquitin chains relies upon the ubiquitin-binding domain (UBD) that overlaps with the MOD [66,67] (Fig. 5). Since ubiquitin-binding by NEMO is required for the induced activation of the IKK complex, it is possible that either or both of these novel CPP-Is disrupt this process. Further work is therefore required to determine precisely whether NEMO oligomerization or ubiquitin binding (or both processes) is the critical target of the CC2 or LZ peptides. Nevertheless, it remains clear that these peptides effectively block signal-induced NF- κ B activity in cells and, collectively, the studies of Agou et al. have firmly established both the target-binding specificity and pathway-selectivity of these novel CPP-Is targeting the MOD/UBD domain.

Functional studies of AntP-NEMO-CC2 and –LZ demonstrated that both peptides significantly enhanced the apoptosis of a retinoblastoma cell line that requires constitutive NF- κ B activity for survival [68]. This finding was further supported by the recent demonstration that AntP-NEMO-LZ induced cell death in a panel of human myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) cell lines as well as in bone marrow cells derived from high-risk MDS and AML patients [24]. Intriguingly this latter study was performed using a version of the NEMO-LZ peptide fused with a poly-arginine-based CPP (R7:RRRRRRRLKAQA) in place of AntP, thereby demonstrating the interchangeability of separate CPPs to effectively deliver the same cargo. Taken together therefore, these initial cell-based biological studies of the CC2 and LZ peptides provide convincing proof of principle for this approach and raise the exciting prospect of future studies using these CPP-Is to target the MOD/UBD domain of NEMO *in vivo*.

Inhibitors of p65 phosphorylation

The first CPP-Is specifically developed to interfere with the phosphorylation of NF- κ B proteins target the prototypic classical p65 subunit. Serine phosphorylations at positions 276, 529 and

536 have been shown to be required for the normal transactivating function of p65 [54,55, 181] and armed with this understanding Takada and colleagues designed a panel of peptides targeting these residues [182]. To target S276, a peptide including this residue (bold and underlined: ²⁷¹QLRRPSDRELSE²⁸²) was fused with AntP and this CPP-I was named AntP-p65-P1. A second CPP-I named AntP-p65-P6 was also generated that encompassed both S529 and S536 (⁵²⁵NGLLSGDEDFSS⁵³⁷). Both of these CPP-Is effectively blocked TNF-, LPS- and IL-1-induced NF-κB activation in KBM-5 chronic myeloid leukemia cells whereas neither prevented the phosphorylation or degradation of IκBα or TNF-induced AP-1 activation. Instead, these peptides prevented the phosphorylation of p65 and blocked its nuclear translocation and transcriptional activity. Furthermore, AntP-p65-P1 was shown to inhibit NF-κB-dependent gene expression (i. e. CyclinD1, COX2 and MMP9). Importantly replacing S276 with alanine abrogated the inhibitory activity of the peptide thereby providing both target verification and a convenient control peptide for experiments utilizing this reagent. The biological activity of AntP-p65-P1 was established in studies of human head and neck squamous cell carcinoma cells in which it blocked both constitutive NF-κB activity and cell proliferation [156]. Furthermore, AntP-p65-1 rendered KBM-5 cells susceptible to TNF-induced apoptosis, once again highlighting both the critical role of NF-κB in tumor cell proliferation and survival and the ability of target-specific CPP-Is to block this pathophysiological function of NF-κB [156,182]. These CPP studies therefore identify p65 phosphorylation as a realistic target for the development of NF-κB-specific drugs and provide valuable insight supporting further efforts aimed at using CPPs to directly target post-translational modifications of the NF-κB proteins.

CPP-Is targeting IκBα

Another group of CPP-Is that inhibit NF-κB activation by blocking a critical phosphorylation event does so by specifically targeting IκBα. Since the phosphorylation of Serines 32 and 36 is required for the subsequent ubiquitination and degradation of IκBα in the classical pathway, these CPP-Is target this region of the protein. Notably, each of these CPP-Is consists of a CPP fused with a whole (or truncated) IκBα protein and, as such, these are the only examples of whole protein or large polypeptide transduction approaches currently directed at the NF-κB pathway. This group of CPP-IκBα chimeras was constructed by subcloning the IκBα cDNA into expression vectors harboring the appropriate CPP sequence together with an epitope tag (e.g. His, HA or GST). The CPP-I fusion proteins were then expressed and biochemically purified using the convenient tags and then used to transduce target cells or inject *in vivo*.

The original IκBα-specific CPP-Is consisted of the full-length IκBα protein in which S32 and 36 are substituted with alanine that was preceded at the NH₂-terminus by TAT [183,184]. This construct is named the TAT super-repressor or TAT-srIκBα and it has been used to block IL-1β- and TNF-induced NF-κB activation in HeLa, A459 and Jurkat cells without affecting ERK, JNK or p38 MAP kinase signaling [183,184]. TAT-srIκBα also renders eosinophils more susceptible to TNF-induced apoptosis [183] and it has been used *in vivo* to block carrageenan-induced pleurisy in rats following intravenous injection [185]. A second CPP-I that targets IκBα consists of amino acids 37 – 317 (i. e. the whole protein minus the NH₂-terminal phosphorylation domain) fused with MTS as the CPP at the COOH-terminus [186]. This MTS-IκBα(ΔN) construct inhibited NF-κB activation in NIH-3T3 cells and primary thymocytes and functioned *in vivo* to block NF-κB activity in mouse skin after wounding. Intravenous injection of MTS-IκBα(ΔN) also inhibited endotoxin-induced NF-κB activation and the resulting change in pulmonary vascular resistance in sheep lungs thereby demonstrating the effectiveness of this CPP-I in large mammal models [186].

The future of CPPs in NF- κ B research

The studies described above clearly demonstrate that CPP-mediated transduction can be effectively used to inhibit classical NF- κ B activation induced by a wide range of stimuli in many different cell types. Most exciting however is the ability of CPP-Is targeting NF- κ B to function *in vivo* in established models of disease. The full potential of the NF- κ B CPP-Is that have been developed has not yet been realized and we predict that these reagents will be used increasingly frequently by researchers wishing to selectively inhibit NF- κ B signaling at well-defined molecular targets. Furthermore, as we better understand the unique signaling components that function in the myriad of pathways leading to the many NF- κ B transcriptional responses, the future use of CPPs to target these will most likely proliferate. We therefore anticipate that more CPP-Is targeting NF- κ B activation will emerge and that these will disrupt novel interactions or signaling events within the many pathways that are currently under investigation.

Expansion of our knowledge of NF- κ B signaling will be accompanied by greater insight into the mechanisms, capabilities and limitations of peptide transduction technology. In particular, the precise mechanisms of cellular entry and intracellular release of each of the classes of CPPs will be characterized. This understanding will permit the design of new generations of synthetic CPPs with improved transduction, cargo release and target accessing capabilities. New classes of CPPs will also be identified and used to deliver NF- κ B-directed cargos. In this regard, small pentapeptide CPPs (named CPP5s) derived from a Bax (Bcl2-associated X protein)-binding partner were identified recently and shown to rapidly enter many cell types in an endocytosis- and pinocytosis-independent manner [187]. CPP5s exhibited very low toxicity in cells and *in vivo* and it is therefore likely that these will be tested in the near future for their ability to deliver cargos directed at the NF- κ B signaling pathways.

Advancement will also be made in determining the pharmacokinetics of the separate classes of CPPs and, more importantly, the CPP-Is targeting NF- κ B. TAT has been shown to deliver bioactive cargo to all tissues in mice [42,43] and in a recent study, Cai and colleagues described the tissue distribution kinetics of a TAT fusion with β -galactosidase following oral, i. v., i. p and portal vein administration [44]. Although this was not a definitive pharmacokinetic study, the encouraging results provide the basis for future in-depth studies and lend strong support to the use of TAT in developing peptide transduction-based therapies. Accumulated evidence from *in vivo* studies of the NBD peptide demonstrates its efficacy in models of diseases in a wide array of distinct tissues. Furthermore, the NBD has been administered via numerous routes including i. p., intranasal, intracranial and topical, and it has proven to be effective in each case [64,121,129,163,167,168,172–176]. This therefore suggests that this CPP-I has good absorption and tissue distribution kinetics; the precise details of these critical pharmacokinetic parameters, however, remain to be definitively determined. Furthermore, the metabolism and / or excretion of the NF- κ B-targeting CPP-Is have not been reported and the potential for detrimental immunogenicity of these peptides has not yet been addressed. Finally, although the ability of each of the CPPs to traverse the blood-brain barrier and enter the CNS may provide the exciting capability of targeting bioactive cargo to these tissues [145,172,174–176], the possibility of neurotoxicity must be very carefully considered when pursuing these approaches. Clearly, obtaining a detailed understanding of the pharmacokinetics of the individual CPP-Is should be an area of intense effort in the near future if the ultimate goal of bringing these reagents to the clinic is to be attained.

Recent evidence suggests that the efficacy of the NBD peptide *in vivo* varies among disease models and is dependent upon the CPP with which it is coupled [25]. A better understanding of how the biophysical properties of the CPPs affect their pharmacokinetics will therefore allow for more informed and rational selection of the CPP-cargo combinations to most effectively target NF- κ B *in vivo*. One related issue that has yet to be addressed in the peptide transduction

field is the ubiquitous ability of CPPs to enter all cell types and tissues *in vivo* [13]. In designing strategies to specifically block aberrant NF- κ B signaling at sites of disease it would be extremely beneficial to be able to target the delivery of the CPP-Is to only those tissues. We therefore predict that inroads will be made into identifying methods to selectively target CPPs to diseased tissues such as chronic inflammatory lesions or tumors, indeed Myrberg and colleagues have recently described a tumor-targeting peptide sequence that may facilitate this [188]. One further possibility may be the development of synthetic micelle-based carrier approaches to “cage” the CPP-I, then deliver it directly into the local cellular environment at sites of disease. To do this micelles would need to be engineered to selectively home to disease sites possibly by binding to cell surface proteins only expressed in cells present within diseased tissue (e.g. leukocyte adhesion molecules on endothelial cells at sites of inflammation, tumor-specific antigens).

One of the exciting consequences of targeting NF- κ B signaling using CPP-Is is the ability of this relatively straightforward technique to validate potential drug targets in cells and *in vivo*. This “proof-of-principle” that CPP-Is provide might then lead to the further development of new generations of drugs directed against those validated targets. Examples of how this has already occurred include the development of an effective peptidomimetic compound modeled upon the BB loops in the TIR domain of MyD88 that blocks IL-1 and TLR signaling [84]. This work emerged directly from studies of CPP-Is targeting the same domain [83]. Using a separate and insightful approach, Wyler and colleagues recently used the identification of CPP-Is targeting the ubiquitin-binding / MOD of NEMO [68] as the rational basis to generate a panel of designed ankyrin repeat proteins (DARPs) directed against the same domains [189]. These DARPs blocked NEMO oligomerization and prevented TNF-induced NF- κ B activation in cells. Approaches such as these may have advantages such as better stability *in vivo*, potentially higher target affinity and lower costs of production over using CPP-Is themselves as drugs. However the well-established ability of CPP-Is to function *in vivo* warrants further intense investigation of peptide transduction as a means in its own right to deliver NF- κ B targeting drugs.

Novel targets for NF- κ B-specific CPP-Is

A major challenge facing pharmaceutical companies is the development of highly specific NF- κ B inhibitors that block only aberrant signaling and maintain normal physiological responses. The importance of this is highlighted by a growing number of genetic studies in mice demonstrating detrimental effects of tissue-specific deletion of components of the IKK complex [190]. In this regard, two recent reports showed that deleting either NEMO or IKK β from intestinal epithelial cells leads to severe disruption of immune homeostasis in the gastrointestinal tract and results in chronic inflammation resembling inflammatory bowel disease [137,191]. Other examples of deleterious effects are the increased development of hepatocellular carcinoma in mice with a targeted deletion of NEMO in hepatocytes [192, 193] and the development of inflammatory skin disease in mice lacking IKK β in keratinocytes [194]. Contrasting these studies, CNS-restricted deletion of NEMO and IKK β ameliorated autoimmune encephalomyelitis in mice, thereby demonstrating the key role of the classical NF- κ B pathway in promoting the inflammation associated with this disease [195]. Nevertheless, the severe detrimental effects of deleting IKK complex subunits in some cell types *in vivo* cannot be overlooked as they suggest that systemic inhibition of NF- κ B signaling might have damaging consequences. Notably however, the majority of pharmacological approaches that have been used to target NF- κ B *in vivo* have not resulted in deleterious pathology [6]. This is supported by the increasing number of reports of effective amelioration of inflammatory disease using the NBD peptide (discussed in detail earlier). For example, although genetic deletion of IKK β and NEMO had profound pro-inflammatory effects in the gut [137,191], treatment of mice with the NBD peptide prevented inflammation in murine

models of colitis and necrotizing enterocolitis [165–167]. It is therefore difficult to determine whether genetic deletion of separate IKK complex subunits is an absolute predictor of the likely effects of pharmaco-logically targeting IKK activation. One example of where this does appear to be the case is a recent report by Greten and colleagues who showed that deletion of IKK β in myeloid cells led to increased endotoxic shock due to enhanced IL-1 β processing [196]. These results were recapitulated in wild-type mice following prolonged pharmacologic inhibition of IKK β high-lighting the potential problems associated with long term IKK β inhibition. Clearly, therefore, any drugs targeting the NF- κ B pathway must be used with caution and the more selective a drug can be made for specific upstream signaling pathways to NF- κ B, the better that drug will be. The ability of CPP-Is to deliver cargos directed at specific molecular interactions or signaling events provides a convenient method to effectively accomplish this critical pathway selectivity.

One example of how pathway specificity has already been achieved using a CPP-I is the AntP-TIRAP peptide, described by Horng and colleagues, that blocks signaling via TLR4 but does not affect NF- κ B activation by TLR9 [81]. This occurs because TIRAP is a TLR4- but not TLR9-specific adaptor protein, thereby highlighting the importance of identifying more pathway-specific targets upstream of NF- κ B that can be accessed using CPP-Is. An important target protein that could be potentially exploited in this regard is NEMO. The two CPP-I approaches already targeting NEMO inhibit all classical signaling to NF- κ B by blocking critical NEMO functions (i. e. IKK binding and oligomerization respectively). However, mutations within NEMO occur in a panel of inherited human diseases and the effects of these mutations range from either complete loss of function to inhibition of distinct subsets of signaling pathways to NF- κ B [197,198]. For example, certain mutations in the COOH-terminus of NEMO block NF- κ B activation in response to TNF but not IL-1 [199]. This is also illustrated by the finding that some of these mutations impair the function of the TNF superfamily receptor CD40 on B cells, whereas many mutations elsewhere in NEMO do not (207). These findings strongly suggest that distinct domains of NEMO are required to respond to separate upstream signaling pathways. It is therefore intriguing to speculate that CPP-Is specifically designed to interfere with individual domains or specific posttranslational modifications within NEMO may be able to differentially block signaling leading to classical NF- κ B activation.

Another exciting prospect is the generation of CPP-Is specific for the non-canonical NF- κ B pathway. All of the current CPP-Is targeting NF- κ B disrupt the classical pathway and none have been tested for effects on non-canonical NF- κ B activation. While it is possible that the SN50 peptide may affect the nuclear translocation of non-canonical NF- κ B heterodimers (i. e. p52:RelB) and that the NBD peptide may affect the function of IKK α by disrupting the endogenous IKK complex, no evidence for this has yet been provided. We predict therefore that novel peptides specifically disrupting unique components or signaling events in the non-canonical pathway possibly upstream of IKK α activation (i. e. blocking TRAF3 and/ or NIK function) will soon be developed to allow researchers to conveniently dissect these pathways in cells and *in vivo*. In addition to being the effector kinase in the non-canonical pathway, it has become clear that IKK α also functions independently of NEMO and IKK β in the nucleus [200–202]. In this setting, IKK α appears to regulate chromatin structure around NF- κ B-inducible gene promoters by phosphorylating histones or other proteins involved in chromatin remodeling and gene transcription [200–202]. As the major classes of CPPs can enter the nucleus, it may be possible in the future to specifically target these nuclear functions of IKK α using novel CPP-Is.

The full potential of whole protein CPP-Is for modulating NF- κ B signaling has not yet been explored. To date only I κ B α has been targeted using CPPs fused with whole proteins [183–186]; there appears to be no limitation to the power of this approach, however, to manipulate NF- κ B. Proteins that could be transduced might include dominant negative versions of

pathway-specific kinases. For example, selective ablation of the classical pathway might be possible using CPP-tagged kinase-dead IKK β whereas inactive IKK α or NIK might effectively block non-canonical signaling. Furthermore, although all of the current NF- κ B specific CPP-cargos function as inhibitors of the pathway, it will be possible using whole protein transduction to deliver active signaling intermediates to selectively induce or upregulate distinct pathways. While whole protein transduction may not be best suited for clinical use, it provides researchers with a very convenient method for assessing the effects of immediate expression of exogenous proteins in target cells.

The exciting potential of *in vivo* delivery

The importance of the ability of CPPs to deliver cargo targeting NF- κ B activation *in vivo* cannot be overstated. This capability has allowed basic researchers to translate *in vitro* and cell-based findings into relevant animal models, and the potential for applying CPPs to the study the pathophysiological role of NF- κ B in disease is immense. The best-studied NF- κ B targeting CPP-I in this regard is the NBD peptide that has been shown to effectively ameliorate disease in multiple *in vivo* models of acute and chronic inflammation [25,64,113,121,¹⁴⁵,¹⁶³,165,169,172,177]. In light of these very promising results it may not be long before clinical trials of drugs aimed at blocking NF- κ B signaling at the NBD are underway. Recent studies by major pharmaceutical companies that have precisely defined the structure of the NBD suggest that this exciting prospect may indeed be close at hand [106,108]. As new pathway-specific CPP-Is are developed, these too will be tested *in vivo* for selective effects on aberrant signaling in disease and this will pave the way for novel therapeutics aimed at these validated targets. It is particularly intriguing to note that CPP-Is targeting NF- κ B have been successfully tested in large animal models (i. e. piglets and sheep) [169,186] as these more closely resemble the human situation. CPPs may therefore bring us one step closer to realizing the long sought after goal of developing pathway-specific and clinically safe NF- κ B inhibiting drugs.

Summary

CPP technology provides the NF- κ B field with a convenient and well-established method to generate useful experimental tools for dissecting this ever more complex signaling paradigm. As we continue to unravel the plethora of interaction domains and post translational modifications that function in the many pathways leading to NF- κ B activation, it is likely that realistic targets for the development of novel blocking peptides, substrate decoys or other domains will arise. The relative ease of generation of CPP-Is aimed at these novel targets will put target validation in cells and *in vivo* into the hands of researchers. To date, several CPP-Is targeting the classical NF- κ B pathway have been developed and some of these have been demonstrated to be highly effective *in vivo*. Most notably, the NBD peptide that blocks the association of NEMO with IKK α and IKK β has been shown to inhibit NF- κ B and ameliorate disease in models of acute and chronic inflammation. These findings establish an exciting blueprint for the future development of novel CPP-Is targeting the many separate upstream signaling pathways that activate classical and non-canonical NF- κ B. The most exciting aspect of these studies is the very real promise that CPP-Is offer for translating basic research into effective clinical strategies. In the continuing effort to bring NF- κ B inhibitors from the bench to the bedside, CPP-Is represent a very attractive, realistic and attainable first step in realizing this fundamental objective.

Acknowledgments

Work in the authors' laboratories is supported by the National Institutes of Health HL080612 (MJM) and AI067946, AI079731 (JSO).

References

1. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives *Oncogene* 2006;25:6680–6684.
2. Hayden MS, Ghosh S. Signaling to NF-kappaB *Genes Dev.* 2004;18:2195–2224.
3. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling *Cell.* 2008;132:344–362.
4. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit *Nat. Rev. Cancer* 2002;2:301–310.
5. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. *Nat. Rev. Drug Discov* 2004;3:17–26. [PubMed: 14708018]
6. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. *Oncogene* 2006;25:6887–6899. [PubMed: 17072334]
7. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends Immunol* 2004;25:280–288. [PubMed: 15145317]
8. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases *Sci. STKE* 2006. 2006 re13.
9. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. *Oncogene* 2006;25:6685–6705. [PubMed: 17072322]
10. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. *Cell. Mol. Life Sci* 2005;62:1839–1849. [PubMed: 15968462]
11. Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. *Adv. Drug Deliv. Rev* 2005;57:547–558. [PubMed: 15722163]
12. Lindsay MA. Peptide-mediated cell delivery: application in protein target validation. *Curr. Opin. Pharmacol* 2002;2:587–594. [PubMed: 12324264]
13. Wadia JS, Dowdy SF. Protein transduction technology. *Curr. Opin. Biotechnol* 2002;13:52–56. [PubMed: 11849958]
14. Kabouridis PS. Biological applications of protein transduction technology. *Trends Biotechnol* 2003;21:498–503. [PubMed: 14573363]
15. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. *Adv. Drug Deliv. Rev* 2005;57:529–545. [PubMed: 15722162]
16. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. *J. Biol. Chem* 2002;277:30208–30218. [PubMed: 12034749]
17. Futaki S. Arginine-rich peptides: potential for intra-cellular delivery of macromolecules and the mystery of the translocation mechanisms. *Int. J. Pharm* 2002;245:1–7. [PubMed: 12270237]
18. Fischer PM, Krausz E, Lane DP. Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. *Bioconjug. Chem* 2001;12:825–841. [PubMed: 11716670]
19. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. *Cell* 1988;55:1179–1188. [PubMed: 2849509]
20. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. *Cell* 1988;55:1189–1193. [PubMed: 2849510]
21. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J. Biol. Chem* 1997;272:16010–16017. [PubMed: 9188504]
22. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. *J. Biol. Chem* 1994;269:10444–10450. [PubMed: 8144628]
23. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. *J. Biol. Chem* 1996;271:18188–18193. [PubMed: 8663410]
24. Carvalho G, Fabre C, Braun T, Grosjean J, Ades L, Agou F, Tasdemir E, Boehrer S, Israel A, Veron M, Fenaux P, Kroemer G. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces

- apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. *Oncogene* 2007;26:2299–2307. [PubMed: 17043643]
25. Tilstra J, Rehman KK, Hennon T, Plevy SE, Clemens P, Robbins PD. Protein transduction: identification, characterization and optimization. *Biochem. Soc. Trans* 2007;35:811–815. [PubMed: 17635154]
 26. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. *J. Biol. Chem* 1995;270:14255–14258. [PubMed: 7782278]
 27. Berlose JP, Convert O, Derossi D, Brunissen A, Chassaing G. Conformational and associative behaviours of the third helix of antennapedia homeodomain in membrane-mimetic environments. *Eur. J. Biochem* 1996;242:372–386. [PubMed: 8973656]
 28. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. *Trends Cell Biol* 1998;8:84–87. [PubMed: 9695814]
 29. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. *J. Control Release* 2005;102:247–253. [PubMed: 15653149]
 30. Letoha T, Gaal S, Somlai C, Venkei Z, Glavinas H, Kusz E, Duda E, Czajlik A, Petak F, Penke B. Investigation of penetratin peptides. Part 2. In vitro uptake of penetratin and two of its derivatives. *J. Pept. Sci* 2005;11:805–811. [PubMed: 15942927]
 31. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. *J. Biol. Chem* 2005;280:15300–15306. [PubMed: 15687490]
 32. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. *J. Biol. Chem* 2003;278:585–590. [PubMed: 12411431]
 33. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat. Med* 2004;10:310–315. [PubMed: 14770178]
 34. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT) “protein transduction domains” promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. *J. Biol. Chem* 2003;278:35109–35114. [PubMed: 12837762]
 35. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. *J. Biol. Chem* 2002;277:2437–2443. [PubMed: 11711547]
 36. Veach RA, Liu D, Yao S, Chen Y, Liu XY, Downs S, Hawiger J. Receptor/transporter-independent targeting of functional peptides across the plasma membrane. *J. Biol. Chem* 2004;279:11425–11431. [PubMed: 14699109]
 37. Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladriere L, Allaman-Pillet N, Poirot O, Kellenberger S, Beckmann JS, Eizirik DL, Bonny C, Maurer F. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. *Biochim. Biophys. Acta* 2007;1768:2222–2234. [PubMed: 17626783]
 38. Jones SW, Christison R, Bundell K, Joyce CJ, Brockbank SM, Newham P, Lindsay MA. Characterisation of cell-penetrating peptide-mediated peptide delivery. *Br. J. Pharmacol* 2005;145:1093–1102. [PubMed: 15937518]
 39. El-Andaloussi S, Jarver P, Johansson HJ, Langel U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. *Biochem. J* 2007;407:285–292. [PubMed: 17627607]
 40. Bogoyevitch MA, Kendrick TS, Ng DC, Barr RK. Taking the cell by stealth or storm? Protein transduction domains (PTDs) as versatile vectors for delivery. *DNA Cell Biol* 2002;21:879–894. [PubMed: 12573048]
 41. Zhang L, Torgerson TR, Liu XY, Timmons S, Colosia AD, Hawiger J, Tam JP. Preparation of functionally active cell-permeable peptides by single-step ligation of two peptide modules. *Proc. Natl. Acad. Sci. U S A* 1998;95:9184–9189. [PubMed: 9689055]
 42. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. *Proc. Natl. Acad. Sci. U S A* 1994;91:664–668. [PubMed: 8290579]

43. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science* 1999;285:1569–1572. [PubMed: 10477521]
44. Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. The kinetics and tissue distribution of protein transduction in mice. *Eur. J. Pharm. Sci* 2006;27:311–319. [PubMed: 16376528]
45. Barka T, Van der Noen HM. Retrovirus-mediated gene transfer into salivary glands in vivo. *Hum. Gene Ther* 1996;7:613–618. [PubMed: 8845386]
46. Barka T, van der Noen HM. Retrovirus-mediated gene transfer into rat salivary gland cells in vitro and in vivo. *J. Histochem. Cytochem* 1997;45:1533–1545. [PubMed: 9358855]
47. Barka T, Gresik EW, van Der Noen H. Transduction of TAT-HA-beta-galactosidase fusion protein into salivary gland-derived cells and organ cultures of the developing gland, and into rat submandibular gland in vivo. *J. Histochem. Cytochem* 2000;48:1453–1460. [PubMed: 11036088]
48. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, Kimura M, Ozaki D, Yamagata K, Ohta S. Protection against ischemic brain injury by protein therapeutics. *Proc. Natl. Acad. Sci. U S A* 2002;99:17107–17112. [PubMed: 12475933]
49. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J. In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. *J. Neurosci* 2002;22:5423–5431. [PubMed: 12097494]
50. Kilic U, Kilic E, Dietz GP, Bahr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. *Stroke* 2003;34:1304–1310. [PubMed: 12677018]
51. Jo D, Nashabi A, Doxsee C, Lin Q, Unutmaz D, Chen J, Ruley HE. Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. *Nat. Biotechnol* 2001;19:929–933. [PubMed: 11581657]
52. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. *Nat. Med* 2000;6:1362–1367. [PubMed: 11100121]
53. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. *J. Biol. Chem* 2000;275:32592–32597. [PubMed: 10938077]
54. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A, Doi T, Saiki I. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. *J. Biol. Chem* 2003;278:36916–36923. [PubMed: 12842894]
55. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). *EMBO J* 2003;22:1313–1324. [PubMed: 12628924]
56. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. *Mol. Cell* 2002;9:625–636. [PubMed: 11931769]
57. Li Q, Estepa G, Memet S, Israel A, Verma IM. Complete lack of NF-kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. *Genes Dev* 2000;14:1729–1733. [PubMed: 10898787]
58. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. *Science* 1999;284:321–325. [PubMed: 10195897]
59. Li ZW, Chu WH, Yu Y, Delhase M, Deerinc T, Ellisman M, Johnson R, Karin M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. *J. Exp. Med* 1999;189:p1839–1845.
60. Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, Schwarz T, Feng L, Johnson RS, Karin M. Female mice heterozygous for IKK gamma/ NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. *Mol. Cell* 2000;5:969–979. [PubMed: 10911991]
61. Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J, Elia AJ, Mak TW. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. *Genes Dev* 2000;14:854–862. [PubMed: 10766741]

62. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. *Cell* 2001;107:763–775. [PubMed: 11747812]
63. Solt LA, Madge LA, Orange JS, May MJ. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. *J. Biol. Chem* 2007;282:8724–8733. [PubMed: 17244613]
64. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. *Science* 2000;289:1550–1554. [PubMed: 10968790]
65. May MJ, Marienfeld RB, Ghosh S. Characterization of the Ikappa B-kinase NEMO binding domain. *J. Biol. Chem* 2002;277:45992–46000. [PubMed: 12244103]
66. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. *Mol. Cell* 2006;22:245–257. [PubMed: 16603398]
67. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. *Nat. Cell Biol* 2006;8:398–406. [PubMed: 16547522]
68. Agou F, Courtois G, Chiaravalli J, Baleux F, Coic YM, Traincard F, Israel A, Veron M. Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. *J. Biol. Chem* 2004;279:54248–54257. [PubMed: 15466857]
69. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF, Ogura Y, Nunez G. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. *J. Biol. Chem* 2000;275:27823–27831. [PubMed: 10880512]
70. Fontan E, Traincard F, Levy SG, Yamaoka S, Veron M, Agou F. NEMO oligomerization in the dynamic assembly of the IkappaB kinase core complex. *FEBS J* 2007;274:2540–2551. [PubMed: 17419723]
71. Tegethoff S, Behlke J, Scheidereit C. Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation. *Mol. Cell. Biol* 2003;23:2029–2041. [PubMed: 12612076]
72. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. *Nat. Immunol* 2002;3:958–965. [PubMed: 12352969]
73. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ, Klaus GG, Johnston LH, Ley SC. CD40 regulates the processing of NF-kappaB2 p100 to p52. *EMBO J* 2002;21:5375–5385. [PubMed: 12374738]
74. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. *Immunity* 2002;17:525–535. [PubMed: 12387745]
75. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. *Science* 2001;293:1495–1499. [PubMed: 11520989]
76. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IKKalpha to p100 and IKKalpha-mediated phosphorylation. *J. Biol. Chem* 2004;279:30099–30105. [PubMed: 15140882]
77. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. *Mol. Cell* 2001;7:401–409. [PubMed: 11239468]
78. Yin L, Wu L, Wesche H, Arthur CD, White JM, Goeddel DV, Schreiber RD. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. *Science* 2001;291:2162–2165. [PubMed: 11251123]
79. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the Nf-kb inducing kinase by TRAF3-induced degradation. *J. Biol. Chem* 2004;279:26243–26250. [PubMed: 15084608]
80. Toshchakov VY, Fenton MJ, Vogel SN. Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs. *J. Immunol* 2007;178:2655–2660. [PubMed: 17312106]
81. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. *Nat. Immunol* 2001;2:835–841. [PubMed: 11526399]

82. Jeyaseelan S, Manzer R, Young SK, Yamamoto M, Akira S, Mason RJ, Worthen GS. Toll-IL-1 receptor domain-containing adaptor protein is critical for early lung immune responses against *Escherichia coli* lip-opolysaccharide and viable *Escherichia coli*. *J. Immunol* 2005;175:7484–7495. [PubMed: 16301656]
83. Loiarro M, Sette C, Gallo G, Ciacchi A, Fanto N, Mastroianni D, Carminati P, Ruggiero V. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF- κ B. *J. Biol. Chem* 2005;280:15809–15814. [PubMed: 15755740]
84. Loiarro M, Capolunghi F, Fanto N, Gallo G, Campo S, Arseni B, Carsetti R, Carminati P, De Santis R, Ruggiero V, Sette C. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. *J. Leukoc. Biol* 2007;82:801–810. [PubMed: 17548806]
85. Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, Suttles J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. *J. Immunol* 2005;174:1081–1090. [PubMed: 15634933]
86. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dziveno OK, Vologodskaya M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H. Distinct molecular mechanism for initiating TRAF6 signalling. *Nature* 2002;418:443–447. [PubMed: 12140561]
87. Fakrudin JM, Laurence J. Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis. *Clin. Exp. Immunol* 2004;137:538–545. [PubMed: 15320903]
88. Bharti AC, Takada Y, Shishodia S, Aggarwal BB. Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. *J. Biol. Chem* 2004;279:6065–6076. [PubMed: 14645259]
89. Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. *J. Immunol* 1998;161:6084–6092. [PubMed: 9834092]
90. Gorlich D, Vogel F, Mills AD, Hartmann E, Laskey RA. Distinct functions for the two importin subunits in nuclear protein import. *Nature* 1995;377:246–248. [PubMed: 7675110]
91. Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J. Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. *J. Immunol* 1999;163:590–598. [PubMed: 10395645]
92. Hawiger J. Noninvasive intracellular delivery of functional peptides and proteins. *Curr. Opin. Chem. Biol* 1999;3:89–94. [PubMed: 10021415]
93. Liu D, Li C, Chen Y, Burnett C, Liu XY, Downs S, Collins RD, Hawiger J. Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide. *J. Biol. Chem* 2004;279:48434–48442. [PubMed: 15345713]
94. Yan Liu X, Robinson D, Veach RA, Liu D, Timmons S, Collins RD, Hawiger J. Peptide-directed suppression of a pro-inflammatory cytokine response. *J. Biol. Chem* 2000;275:16774–16778. [PubMed: 10751381]
95. Boothby M. Specificity of sn50 for NF-kappa B? *Nat. Immunol* 2001;2:471–472.
96. Maggirwar SB, Sarmiere PD, Dewhurst S, Freeman RS. Nerve growth factor-dependent activation of NF-kappaB contributes to survival of sympathetic neurons. *J. Neurosci* 1998;18:10356–10365. [PubMed: 9852573]
97. Gentry JJ, Casaccia-Bonnel P, Carter BD. Nerve growth factor activation of nuclear factor kappaB through its p75 receptor is an anti-apoptotic signal in RN22 schwannoma cells. *J. Biol. Chem* 2000;275:7558–7565. [PubMed: 10713062]
98. Luo Y, Hattori A, Munoz J, Qin ZH, Roth GS. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-kappaB in rats. *Mol. Pharmacol* 1999;56:254–264. [PubMed: 10419543]
99. Qin ZH, Chen RW, Wang Y, Nakai M, Chuang DM, Chase TN. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. *J. Neurosci* 1999;19:4023–4033.

100. Nakai M, Qin ZH, Chen JF, Wang Y, Chase TN. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. *J. Neuro-chem* 2000;74:647–658.
101. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. *Blood* 2002;99:4079–4086. [PubMed: 12010810]
102. Letoha T, Somlai C, Takacs T, Szabolcs A, Jarmay K, Rakonczay Z Jr, Hegyi P, Varga I, Kaszaki J, Krizbai I, Boros I, Duda E, Kusz E, Penke B. A nuclear import inhibitory peptide ameliorates the severity of chol-ecystokinin-induced acute pancreatitis. *World J. Gastroenterol* 2005;11:990–999. [PubMed: 15742402]
103. Conti E, Uy M, Leighton L, Blobel G, Kuriyan J. Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha. *Cell* 1998;94:193–204. [PubMed: 9695948]
104. Fujihara SM, Cleaveland JS, Grosmaire LS, Berry KK, Kennedy KA, Blake JJ, Loy J, Rankin BM, Ledbetter JA, Nadler SG. A D-amino acid peptide inhibitor of NF-kappa B nuclear localization is efficacious in models of inflammatory disease. *J. Immunol* 2000;165:1004–1012. [PubMed: 10878377]
105. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, Israel A. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. *Cell* 1998;93:1231–1240. [PubMed: 9657155]
106. Rushe M, Silvian L, Bixler S, Chen LL, Cheung A, Bowes S, Cuervo H, Berkowitz S, Zheng T, Guckian K, Pellegrini M, Lugovskoy A. Structure of a NEMO/IKK-Associating Domain Reveals Architecture of the Interaction Site. *Structure* 2008;16:798–808. [PubMed: 18462684]
107. Lo YC, Maddineni U, Chung JY, Rich RL, Myszkowski DG, Wu H. High-affinity interaction between IKKbeta and NEMO. *Biochemistry* 2008;47:3109–3116. [PubMed: 18266324]
108. Strnad J, McDonnell PA, Riexinger DJ, Mapelli C, Cheng L, Gray H, Ryseck RP, Burke JR. NEMO binding domain of IKK-2 encompasses amino acids 735–745. *J. Mol. Recognit* 2006;19:227–233. [PubMed: 16583354]
109. Correa RG, Matsui T, Tergaonkar V, Rodriguez-Esteban C, Izpisua-Belmonte JC, Verma IM. Zebrafish IkappaB kinase 1 negatively regulates NF-kappaB activity. *Curr. Biol* 2005;15:1291–1295. [PubMed: 16051172]
110. Choi M, Rolle S, Wellner M, Cardoso MC, Scheidereit C, Luft FC, Kettritz R. Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis. *Blood* 2003;102:2259–2267. [PubMed: 12763940]
111. Rehman KK, Bertera S, Bottino R, Balamurugan AN, Mai JC, Mi Z, Trucco M, Robbins PD. Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide. *J. Biol. Chem* 2003;278:9862–9868. [PubMed: 12524423]
112. Salanova B, Choi M, Rolle S, Wellner M, Scheidereit C, Luft FC. The effect of fever-like temperatures on neutrophil signaling. *FASEB J* 2005;19:816–818. [PubMed: 15755871]
113. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IkappaB Kinase (IKK) Inhibitor, NEMO-binding Domain Peptide, Blocks Osteoclastogenesis and Bone Erosion in Inflammatory Arthritis. *J. Biol. Chem* 2004;279:37219–37222. [PubMed: 15252035]
114. Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y. Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and cal-varial inflammatory osteolysis. *J. Orthop. Res* 2006;24:1358–1365. [PubMed: 16705717]
115. Gross S, Pownall-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. *Nat. Methods* 2005;2:607–614. [PubMed: 16094386]
116. Paria BC, Malik AB, Kwiatek AM, Rahman A, May MJ, Ghosh S, Tiruppathi C. Tumor necrosis factor-alpha induces nuclear factor-kappaB-dependent TRPC1 expression in endothelial cells. *J. Biol. Chem* 2003;278:37195–37203. [PubMed: 12855710]
117. Paria BC, Bair AM, Xue J, Yu Y, Malik AB, Tiruppathi C. Ca²⁺ influx induced by protease-activated receptor-1 activates a feed-forward mechanism of TRPC1 expression via nuclear factor-kappaB activation in endothelial cells. *J. Biol. Chem* 2006;281:20715–20727. [PubMed: 16709572]

118. Fukushima H, Jimi E, Okamoto F, Motokawa W, Okabe K. IL-1-induced receptor activator of NF-kappaB ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. *Bone* 2005;36:267–275. [PubMed: 15780952]
119. Nadjar A, Tridon V, May MJ, Ghosh S, Dantzer R, Amedee T, Parnet P. NFkappaB activates in vivo the synthesis of inducible Cox-2 in the brain. *J. Cereb. Blood Flow Metab* 2005;25:1047–1059. [PubMed: 15758944]
120. Ramnath RD, Bhatia M. Substance P treatment stimulates chemokine synthesis in pancreatic acinar cells via the activation of NF-kappaB. *Am. J. Physiol. Gastrointest. Liver Physiol* 2006;291:G1113–G1119. [PubMed: 16873895]
121. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. *Nat. Med* 2004;10:617–624. [PubMed: 15156202]
122. Heussler VT, Rottenberg S, Schwab R, Kuenzi P, Fernandez PC, McKellar S, Shiels B, Chen ZJ, Orth K, Wallach D, Dobbelaere DA. Hijacking of host cell IKK signalosomes by the transforming parasite *Theileria*. *Science* 2002;298:1033–1036. [PubMed: 12411708]
123. Petersen CA, Krumholz KA, Carmen J, Sinai AP, Burleigh BA. *Trypanosoma cruzi* infection and nuclear factor kappa B activation prevent apoptosis in cardiac cells. *Infect. Immun* 2006;74:1580–1587. [PubMed: 16495529]
124. Kim JM, Oh YK, Kim YJ, Youn J, Ahn MJ. *Escherichia coli* up-regulates proinflammatory cytokine expression in granulocyte/macrophage lineages of CD34 stem cells via p50 homodimeric NF-kappaB. *Clin. Exp. Immunol* 2004;137:341–350.
125. Schmeck B, Zahlten J, Moog K, van Laak V, Huber S, Hocke AC, Opitz B, Hoffmann E, Kracht M, Zerrahn J, Hammerschmidt S, Rosseau S, Suttorp N, Hippenstiel S. *Streptococcus pneumoniae* induced p38 MAPK dependent phosphorylation of RelA at the interleukin-8 promoter. *J. Biol. Chem* 2004;279:53241–53247. [PubMed: 15485852]
126. N'Guessan PD, Etouem MO, Schmeck B, Hocke AC, Scharf S, Vardarova K, Opitz B, Flieger A, Suttorp N, Hippenstiel S. *Legionella pneumophila*-induced PKCalpha-, MAPK-, and NF-kappaB-dependent COX-2 expression in human lung epithelium. *Am. J. Physiol. Lung Cell. Mol. Physiol* 2007;292:L267–L277. [PubMed: 17012371]
127. N'Guessan PD, Hippenstiel S, Etouem MO, Zahlten J, Beermann W, Lindner D, Opitz B, Witzentrath M, Rosseau S, Suttorp N, Schmeck B. *Streptococcus pneumoniae* induced p38 MAPK- and NF-kappaB-dependent COX-2 expression in human lung epithelium. *Am. J. Physiol. Lung Cell. Mol. Physiol* 2006;290:L1131–L1138. [PubMed: 16414978]
128. Slevogt H, Schmeck B, Jonat C, Zahlten J, Beermann W, van Laak V, Opitz B, Dietel S, N'Guessan PD, Hippenstiel S, Suttorp N, Seybold J. *Moraxella catarrhalis* induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. *Am. J. Physiol. Lung Cell. Mol. Physiol* 2006;290:L818–L826. [PubMed: 16399788]
129. Haeberle HA, Casola A, Gatalica Z, Petronella S, Dieterich HJ, Ernst PB, Brasier AR, Garofalo RP. IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection. *J. Virol* 2004;78:2232–2241. [PubMed: 14963119]
130. Kim JM, Kim JS, Lee JY, Kim YJ, Youn HJ, Kim IY, Chee YJ, Oh YK, Kim N, Jung HC, Song IS. Vacuolating cytotoxin in *Helicobacter pylori* water-soluble proteins upregulates chemokine expression in human eosinophils via Ca²⁺ influx, mitochondrial reactive oxygen intermediates, and NF-kappaB activation. *Infect. Immun* 2007;75:3373–3381. [PubMed: 17452475]
131. Kim JM, Lee JY, Yoon YM, Oh YK, Youn J, Kim YJ. NF-kappa B activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with *Clostridium difficile* toxin A. *Scand. J. Immunol* 2006;63:453–460. [PubMed: 16764699]
132. Fan J, Malik AB. Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. *Nat. Med* 2003;9:315–321. [PubMed: 12592402]
133. De Plaen IG, Han XB, Liu X, Hsueh W, Ghosh S, May MJ. Lipopolysaccharide induces CXCL2/macro-phage inflammatory protein-2 gene expression in enterocytes via NF-kappaB activation: independence from endogenous TNF-alpha and platelet-activating factor. *Immunology* 2006;118:153–163. [PubMed: 16771850]

134. Fan J, Frey RS, Malik AB. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. *J. Clin. Invest* 2003;112:p1234-1243.
135. Gelman AE, Zhang J, Choi Y, and Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. *J. Immunol* 2004;172:6065–6073. [PubMed: 15128790]
136. Zhou X, Gao XP, Fan J, Liu Q, Anwar KN, Frey RS, Malik AB. LPS activation of Toll-like receptor 4 signals CD11b/CD18 expression in neutrophils. *Am. J. Physiol. Lung Cell. Mol. Physiol* 2005;288:L655–L662. [PubMed: 15563689]
137. Zaph C, Troy AE, Taylor BC, Berman-Booty LD, Guild KJ, Du Y, Yost EA, Gruber AD, May MJ, Greten FR, Eckmann L, Karin M, Artis D. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. *Nature* 2007;446:552–556. [PubMed: 17322906]
138. Qi Z, Sun XH. Hyperresponse to T-cell receptor signaling and apoptosis of id1 transgenic thymocytes. *Mol. Cell. Biol* 2004;24:7313–7323. [PubMed: 15314144]
139. Yang Y, Liou HC, Sun XH. Id1 potentiates NF-kappaB activation upon T cell receptor signaling. *J. Biol. Chem* 2006;281:34989–34996. [PubMed: 17012234]
140. Corn RA, Aronica MA, Zhang F, Tong Y, Stanley SA, Kim SR, Stephenson L, Enerson B, McCarthy S, Mora A, Boothby M. T cell-intrinsic requirement for NF-kappa B induction in postdifferentiation IFN-gamma production and clonal expansion in a Th1 response. *J. Immunol* 2003;171:1816–1824. [PubMed: 12902482]
141. Igarashi H, Baba Y, Nagai Y, Jimi E, Ghosh S, Kincade PW. NF-kappaB is dispensable for normal lymphocyte development in bone marrow but required for protection of progenitors from TNFalpha. *Int. Immunol* 2006;18:653–659. [PubMed: 16571606]
142. Tian MT, Gonzalez G, Scheer B, Defranco AL. Bcl10 can promote survival of antigen-stimulated B lymphocytes. *Blood* 2005;106:2105–2112. [PubMed: 15878976]
143. Tas SW, de Jong EC, Hajji N, May MJ, Ghosh S, Vervoordeldonk MJ, Tak PP. Selective inhibition of NF-kappaB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. *Eur. J. Immunol* 2005;35:1164–1174. [PubMed: 15770694]
144. Radhakrishnan S, Nguyen LT, Ciric B, Van Keulen VP, Pease LR. B7-DC/PD-L2 cross-linking induces NF-kappaB-dependent protection of dendritic cells from cell death. *J. Immunol* 2007;178:1426–1432. [PubMed: 17237390]
145. Dasgupta S, Jana M, Zhou Y, Fung YK, Ghosh S, Pahan K. Antineuroinflammatory Effect of NF-kappaB Essential Modifier-Binding Domain Peptides in the Adoptive Transfer Model of Experimental Allergic Encephalomyelitis. *J. Immunol* 2004;173:1344–1354. [PubMed: 15240729]
146. Greten FR, Karin M. The IKK/NF-kappaB activation pathway—a target for prevention and treatment of cancer. *Cancer Lett* 2004;206:193–199. [PubMed: 15013524]
147. Tang F, Tang G, Xiang J, Dai Q, Rosner MR, Lin A. The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. *Mol. Cell. Biol* 2002;22:8571–8579. [PubMed: 12446776]
148. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. *Nat. Cell. Biol* 2001;3:409–416. [PubMed: 11283615]
149. Ravi R, Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). *Cancer Res* 2002;62:1583–1587. [PubMed: 11912124]
150. Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. *Surgery* 2002;132:127–134. [PubMed: 12219002]
151. Biswas DK, Shi Q, Bailly S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kappaB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. *Proc. Natl. Acad. Sci. U S A* 2004;101:10137–10142. [PubMed: 15220474]
152. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. *Mol. cancer Ther* 2007;6:1973–1982. [PubMed: 17620428]

153. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. *Blood* 2003;101:1053–1062. [PubMed: 12393461]
154. Thomas RK, Sos ML, Zander T, Mani O, Popov A, Berenbrinker D, Smola-Hess S, Schultze JL, Wolf J. Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies. *Clin. Cancer Res* 2005;11:8186–8194.
155. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. *Int. J. Cancer* 2003;105:735–746. [PubMed: 12767057]
156. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. *Int. J. Cancer* 2004;111:679–692. [PubMed: 15252836]
157. Mistry P, Deacon K, Mistry S, Blank J, Patel R. NF-kappaB promotes survival during mitotic cell cycle arrest. *J. Biol. Chem* 2004;279:1482–1490. [PubMed: 14581467]
158. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. *Cell* 2003;115:565–576. [PubMed: 14651848]
159. Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. *Biochem. Pharmacol* 2004;67:353–364. [PubMed: 14698047]
160. Craig R, Wagner M, McCardle T, Craig AG, Glembotski CC. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappaB. *J. Biol. Chem* 2001;276:37621–37629. [PubMed: 11448959]
161. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. *Gastroenterology* 2005;128:108–120. [PubMed: 15633128]
162. Mustonen H, Hietaranta A, Puolakkainen P, Kemppainen E, Paimela H, Kiviluoto T, Kivilaakso E. Ethanol induced NF- κ B activation protects against cell injury in cultured rat gastric mucosal epithelium. *Am. J. Physiol. Gastrointest. Liver Physiol* 2007;292:G1614–G1621. [PubMed: 17347452]
163. di Meglio P, Ianaro A, Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. *Arthritis Rheum* 2005;52:951–958. [PubMed: 15751079]
164. Ethridge RT, Hashimoto K, Chung DH, Ehlers RA, Rajaraman S, Evers BM. Selective inhibition of NF-kappaB attenuates the severity of cerulein-induced acute pancreatitis. *J. Am. Coll. Surg* 2002;195:497–505. [PubMed: 12375755]
165. De Plaen IG, Liu SX, Tian R, Neequaye I, May MJ, Han XB, Hsueh W, Jilling T, Lu J, Caplan MS. Inhibition of nuclear factor-kappaB ameliorates bowel injury and prolongs survival in a neonatal rat model of necrotizing enterocolitis. *Pediatr. Res* 2007;61:716–721. [PubMed: 17426653]
166. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, Nakagawa H, Ogura K, Omata M. Cutting Edge: The I κ B Kinase (IKK) Inhibitor, NEMO-Binding Domain Peptide, Blocks Inflammatory Injury in Murine Colitis. *J. Immunol* 2007;179:2681–2685. [PubMed: 17709478]
167. Dave SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, Sepulveda AR, Jobin C, Baldwin AS, Robbins PD, Plevy SE. Amelioration of Chronic Murine Colitis by Peptide-Mediated Transduction of the I κ B Kinase Inhibitor NEMO Binding Domain Peptide. *J. Immunol* 2007;179:7852–7859. [PubMed: 18025231]
168. Chapoval SP, Al-Garawi A, Lora JM, Strickland I, Ma B, Lee PJ, Homer RJ, Ghosh S, Coyle AJ, Elias JA. Inhibition of NF-kappaB activation reduces the tissue effects of transgenic IL-13. *J. Immunol* 2007;179:7030–7041. [PubMed: 17982094]

169. Ankermann T, Reisner A, Wiemann T, Krams M, Kohler H, Krause M F. Topical inhibition of nuclear factor- κ B enhances reduction in lung edema by surfactant in a piglet model of airway lavage. *Crit. Care Med* 2005;33:p1384- 1391.
170. von Bismarck P, Klemm K, Wistadt CF, Winoto-Morbach S, Uhlig U, Schutze S, Uhlig S, Lachmann B, Krause MF. Surfactant “fortification” by topical inhibition of nuclear factor- κ B activity in a newborn piglet lavage model. *Crit. Care Med* 2007;35:2309–2318. [PubMed: 17944019]
171. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J, Bonny C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. *Nat. Med* 2003;9:1180–1186. [PubMed: 12937412]
172. Nadjar A, Bluth RM, May MJ, Dantzer R, Parnet P. Inactivation of the Cerebral NF κ B Pathway Inhibits Interleukin-1 β -Induced Sickness Behavior and c-Fos Expression in Various Brain Nuclei. *Neuropsychopharmacology* 2005;30:1492–1499.
173. van den Tweel ER, Kavelaars A, Lombardi MS, Groenendaal F, May M, Heijnen CJ, van Bel F. Selective inhibition of nuclear factor- κ B activation after hypoxia/ischemia in neonatal rats is not neuroprotective. *Pediatr. Res* 2006;59:232–236. [PubMed: 16439584]
174. Nijboer CH, Heijnen CJ, Groenendaal F, May MJ, van Bel F, Kavelaars A. Strong Neuroprotection by Inhibition of NF- κ B After Neonatal Hypoxia-Ischemia Involves Apoptotic Mechanisms but Is Independent of Cytokines. *Stroke* 2008;39:2129–2137. [PubMed: 18420952]
175. Nijboer CH, Heijnen CJ, Groenendaal F, May MJ, van Bel F, Kavelaars A. A Dual Role of the NF- κ B Pathway in Neonatal Hypoxic-Ischemic Brain Damage. *Stroke*. 2008 (in press).
176. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K. Selective inhibition of NF- κ B activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. *Proc. Natl. Acad. Sci. USA* 2007;104:18754–18759. [PubMed: 18000063]
177. Tas SW, Vervordel donk MJ, Hajji N, May MJ, Ghosh S, Tak PP. Local treatment with the selective I κ B kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. *Arthritis Res. Ther* 2006;8:pR86.
178. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC. Interplay of IKK/NF- κ B signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. *J. Clin. Invest* 2007;117:889–901. [PubMed: 17380205]
179. Lawrence T, Beben M, Liu G, YNizet V, Karin M, IKK α limits macrophage NF- κ B activation and contributes to the resolution of inflammation. *Nature* 2005;434:p1138- 1143.
180. Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F, Verma IM. Enhanced NF- κ B activation and cellular function in macrophages lacking I κ B kinase 1 (IKK1). *Proc. Natl. Acad. Sci. U S A* 2005;102:12425–12430. [PubMed: 16116086]
181. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF- κ B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. *Mol. Cell* 1998;1:661–671. [PubMed: 9660950]
182. Takada Y, Singh S, Aggarwal BB. Identification of a p65 peptide that selectively inhibits NF- κ B activation induced by various inflammatory stimuli and its role in down-regulation of NF- κ B-mediated gene expression and up-regulation of apoptosis. *J. Biol. Chem* 2004;279:15096–15104. [PubMed: 14711835]
183. Fujihara S, Jaffray E, Farrow SN, Rossi AG, Haslett C, Hay RT. Inhibition of NF- κ B by a cell permeable form of I κ B α induces apoptosis in eosinophils. *Biochem. Biophys. Res. Commun* 2005;326:632–637. [PubMed: 15596146]
184. Kabouridis PS, Hasan M, Newson J, Gilroy DW, Lawrence T. Inhibition of NF- κ B activity by a membrane-transducing mutant of I κ B α . *J. Immunol* 2002;169:2587–2593. [PubMed: 12193729]
185. Blackwell NM, Sembi P, Newson JS, Lawrence T, Gilroy DW, Kabouridis PS. Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable I κ B α repressor. *Arthritis. Rheum* 2004;50:2675–2684. [PubMed: 15334484]

186. Mora AL, Lavoy J, McKean M, Stecenko A, Brigham KL, Parker R, Rojas M. Prevention of NF- κ B Activation In vivo by a Cell Permeable NF- κ B Inhibitor Peptide. *Am. J. Physiol. Lung Cell. Mol. Physiol* 2005;289:L536–L544. [PubMed: 15951331]
187. Gomez JA, Gama V, Yoshida T, Sun W, Hayes P, Leskov K, Boothman D, Matsuyama S. Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides. *Biochem. Soc. Trans* 2007;35:797–801. [PubMed: 17635151]
188. Myrberg H, Zhang L, Mae M, Langel U. Design of a tumor-homing cell-penetrating peptide. *Bioconjug. Chem* 2008;19:70–75. [PubMed: 18001077]
189. Wyler E, Kaminska M, Coic YM, Baleux F, Veron M, Agou F. Inhibition of NF- κ B activation with designed ankyrin-repeat proteins targeting the ubiquitin-binding/oligomerization domain of NEMO. *Protein Sci* 2007;16:2013–2022. [PubMed: 17766391]
190. Pasparakis M, Luedde T, Schmidt-Supprian M. Dissection of the NF- κ B signalling cascade in transgenic and knockout mice. *Cell Death Differ* 2006;13:861–872. [PubMed: 16470223]
191. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M. Epithelial NEMO links innate immunity to chronic intestinal inflammation. *Nature* 2007;446:557–561. [PubMed: 17361131]
192. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKK γ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. *Cancer Cell* 2007;11:119–132. [PubMed: 17292824]
193. Wunderlich FT, Luedde T, Singer S, Schmidt-Supprian M, Baumgartl J, Schirmacher P, Pasparakis M, Bruning JC. Hepatic NF- κ B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. *Proc. Natl. Acad. Sci. U S A* 2008;105:1297–1302. [PubMed: 18216263]
194. Stratis A, Pasparakis M, Markur D, Knaup R, Pofahl R, Metzger D, Chambon P, Krieg T, Haase I. Localized inflammatory skin disease following inducible ablation of I κ B kinase 2 in murine epidermis. *J. Invest. Dermatol* 2006;126:614–620. [PubMed: 16397523]
195. van Loo G, De Lorenzi R, Schmidt H, Huth M, Mildner A, Schmidt-Supprian M, Lassmann H, Prinz MR, Pasparakis M. Inhibition of transcription factor NF- κ B in the central nervous system ameliorates autoimmune encephalomyelitis in mice. *Nat. Immunol* 2006;7:954–961. [PubMed: 16892069]
196. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Goktuna SI, Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M. NF- κ B is a negative regulator of IL-1 β secretion as revealed by genetic and pharmacological inhibition of IKK β . *Cell* 2007;130:918–931. [PubMed: 17803913]
197. Orange JS, Geha RS. Finding NEMO: genetic disorders of NF- κ B activation. *J. Clin. Invest* 2003;112:983–985. [PubMed: 14523034]
198. Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate nuclear factor- κ B activation. *Immunol. Rev* 2005;203:21–37. [PubMed: 15661019]
199. Makris C, Roberts JL, Karin M. The carboxyl-terminal region of IkappaB kinase gamma (IKK γ) is required for full IKK activation. *Mol. Cell. Biol* 2002;22:6573–6581. [PubMed: 12192055]
200. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase- α in NF- κ B-dependent gene expression. *Nature* 2003;423:659–663. [PubMed: 12789343]
201. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK- α is critical for cytokine-induced gene expression. *Nature* 2003;423:655–659. [PubMed: 12789342]
202. Hoberg JE, Popko AE, Ramsey CS, Mayo MW. IkappaB kinase α -mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. *Mol. Cell. Biol* 2006;26:457–471. [PubMed: 16382138]

Types of Cargo

Peptides

**Peptides, Proteins,
DNA, RNA, Drugs etc.**

Polypeptides, Proteins

Figure 1.

Methods of generating CPP-Is. Three methods are commonly used to conjugate a bioactive cargo with a CPP and each has been employed to generate CPP-Is targeting the NF- κ B pathway. The types of cargos typically delivered using each of these methods are described (right). (A) Chemical synthesis of chimeric fusions of the cargo with the CPPs. This technique has been the most extensively method employed to generate CPP-Is targeting the NF- κ B pathway [26, 64, 68, 182]. (B) Covalent attachment of the CPP and cargo via a chemical linker such as a cysteine disulfide bridge or a thiazolidine ring. This latter linker has been used to generate a CPP-I targeting NF- κ B nuclear translocation [94]. (C) Cloning and bacterial expression of recombinant proteins using plasmids harboring the CPP as a “tag” has been used to deliver mutated forms of I κ B α to block the NF- κ B pathway [183–186].

Figure 2.

The classical and non-canonical NF-κB pathways. The classical pathway (left) is activated by many stimuli including the proinflammatory cytokines IL-1 and TNF, antigen receptor (TCR, BCR) ligation and signaling from the TLRs. This pathway requires NEMO, and for most stimuli IKKβ is the critical kinase that phosphorylates the IκB proteins, leading to their ubiquitin-dependent proteasomal degradation. The free classical NF-κB complexes (typified by p50:p65) then migrate to the nucleus to regulate the expression of genes involved in responses including immunity, inflammation and cell survival. The non-canonical pathway (right) is activated by a subset of signals including ligation of LTβR, CD40 and BAFF-R, and requires NIK-dependent IKKα activation. It has not yet been formally established whether the

IKK α that functions in the non-canonical pathway exists in a separate complex containing only IKK α (as depicted here and in most models), or if it is the IKK α within the IKK α -IKK β -NEMO holocomplex that is the effector kinase of non-canonical signaling. Activated IKK α phosphorylates the COOH-terminus of p100 complexed with RelB leading to its processing to p52 to generate p52:RelB complexes. This pathway regulates the expression of chemokine and cytokine genes involved in lymphoid organogenesis and B cell maturation. The molecular interactions and the many signaling events that occur up- and downstream of classical and non-canonical NF- κ B activation are discussed in detail in several recent reviews [2,7–9]. In addition, the website maintained by Dr. Thomas Gilmore's group (www.nf-kb.org) is an excellent resource for all aspects of NF- κ B biology.

Figure 3.

CPP-Is that disrupt the classical NF-κB pathway. The cytoplasm of a cell is shown and individual proteins are depicted in different colors. The nucleus is shaded and a nuclear pore indicated by a break in the line representing the nuclear membrane. CPP-Is targeting the classical NF-κB pathway are denoted by the circled red “x” and these are each discussed in detail in the text. The CPP-I between importin and the p50 NLS represents the nuclear localization inhibitors SN50, PN50 and the double NLS construct. The CPP-I between NEMO and IKKβ represents the NBD peptide that blocks association of NEMO with the IKKs and the two CPP-Is between NEMO subunits depict peptides that disrupt NEMO oligomerization. The CPP-I on p65 represents peptides mimicking the phosphorylation sites on p65 and the

CPP-I on I κ B α depicts two constructs that inhibit NF- κ B activation by blocking I κ B α phosphorylation and degradation.

Figure 4.

The NEMO binding domain and the NBD peptide. (A) The catalytic domains, leucine-zippers (L) and helix-loop-helix (H) of IKK α and IKK β are shown and a ubiquitin-like domain present only in IKK β is indicated (U). The position and sequence of the NBD (N) in each kinase is expanded and shown below. (B) Sequences of the wild-type (WT) and mutant (MUT) NBD peptides. The CPP is indicated (oval) and the NBD sequence is shown in upper case. The positions of the alanine-substituted tryptophan residues in the MUT peptide are underlined. CPPs that have been used to deliver the NBD peptide include AntP, TAT and PTD-5 [25,64,111,113].

Figure 5.

CPP-Is targeting NEMO oligomerization. (A) The first and second coiled-coil domains of NEMO are shown in black (CC1 and CC2) and the third coiled-coil that overlaps a leucine zipper region (CC3/LZ) is hatched. The COOH-terminal zinc-finger motif (ZF) and the NH₂-terminal region required for interaction with the NBD in the IKKs are indicated. Shown also is the region encompassing the CC2 and CC3/LZ domains that constitutes the minimal oligomerization domain (MOD) / ubiquitin binding domain (UBD). The positions of the CC2 and LZ regions used for generating the two CPP-Is are drawn (lines) (B) Sequences of the CC2 and LZ peptides. The CPP is indicated (oval) and the protein-derived sequences are shown. The residues in bold and underlined are those encompassing the complete CC2 and LZ domains. CPPs that have been used to deliver these peptides include AntP and R7 [24,68].

Table 1

Commonly used CPPs. The CPPs most commonly used for peptide transduction belong to three separate groups: Cationic, Hydrophobic and Amphipathic. The sequences of the best-characterized members of these groups are shown. Asterisks denote the CPPs that have been used in studies of NF- κ B signaling (see Table 2). The residues of PTD-5 derived from the HIV-1 TAT sequence are underlined. Abbreviations: PTD, peptide transduction domain; MTS, Membrane translocating sequence from the h-region of the Kaposi'

CPP	Sequence	[Ref.]
Cationic		
*HIV-1 TAT fragment (47 – 57)	YGRKKRRQRR	[20]
* <i>Drosophila</i> Antennapedia (43 – 58)	RQIKIWFQNRRMKWKK	[22]
*Poly-arginine (synthetic)	Rn ($n = 7 - 11$)	[16]
*Poly-lysine (synthetic)	Kn ($n = 8 - 10$)	[17]
*PTD-5 (synthetic)	<u>RRQRRTSKLMKR</u>	[16]
Hydrophobic		
*MTS	AAVALLPAVLLALLAP	[26]
Amphipathic		
Transportan (synthetic)	GWTLSAGYLLGKINKALAALAKKIL	[14]
KALA (synthetic)	WEAKLAKALAKALAKHLAKALAKALKACEA	[14]

Table 2

CPP-inhibitors of the classical NF- κ B pathway. Five targets within the classical NF- κ B pathway have been successfully disrupted using CPP-Is (left; see also Fig. 3). The NLS inhibitors block the nuclear localization of several transcription factors including NF- κ B however the remaining CPP-Is exhibit strong specificity for their targets within the NF- κ B pathway (see text and references for details). Sequences of the separate CPPs are shown in Table 1. The residues within some of the cargo sequences that have been mutated to generate inactive mutant versions of the CPP-Is are underlined. Both of the CPP-Is targeting I κ B α are fusions of the CPP with mutant versions of the I κ B α protein. TAT-srI κ B α (sr, super repressor) contains alanines at the critical phosphorylation sites (Ser32 and Ser36) within the N-terminus whereas MTS-I κ B α (κ N) lacks the first 36 N-terminal amino acids. Both fusions act as dominant negatives by preventing phosphorylation of wild-type I κ B α by the IKK complex. The references cited are the original reports for each CPP-I.

Target	CPP-Inhibitor (CPP-I)	Cargo Sequence	[Ref.]
Nuclear Localization Sequence (NLS)	MTS-p50 NLS (SN50)	VQRKRQKLMP	[26]
	MTS-thiazidolino-p50 NLS (ScN50A)	CYVQRKRQKLMP	[41]
	MTS-thiazidolino-p50 NLS (ScN50B)	CYVQRKRQKLMP	[41]
	MTS-SV40 NLS (BMS-205820)	PKKKRKV	[104]
	MTS-c-myc NLS (BMS-214572)	AKRVKL	[105]
	AntP-p50 NLS (PN50)	VQRKRQKLMP	[102]
NEMO Binding Domain (NBD)	AntP-NBD	TALDWSWLQTE	[64]
	TAT-NBD	TALDWSWLQTE	[110]
	PTD-5-NBD	TALDWSWLQTE	[111]
	8K-NBD	TALDWSWLQTE	[167]
	AntP-NEMO-CC2	SKGMQLEDLRQQLQQAEELVAKQELIDKLKEEAQHKIV	[68]
NEMO Oligomerization	AntP-NEMO-LZ	LKAQADIYKADFQAERHAREKLVEKKEYLQEQLQREFNKL	[68]
	R7-NEMO-LZ	LKAQADIYKADFQAERHAREKLVEKKEYLQEQLQREFNKL	[24]
	AntP-p65-P1	QLRRP\$DRELSE	[182]
p65 Phosphorylation	AntP-p65-P6	NGLLS\$GDEDFSS	[182]
I κ B α	TAT-srI α	Full length I κ B α with Ser32 and Ser36 mutated to alanine.	[184]
	MTS-I κ B α (Δ N)	I κ B α mutant lacking residues 1–36	[186]